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Abstract 
Mutations affecting epigenetic regulators and their role 
in peripheral T-cell lymphomas 
Chao Wang, M.D. Ph.D. 
University of Nebraska Medical Center, 2016 
 
Advisor: Wing C. Chan, M.D.  Rakesh K. Singh Ph.D. 
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of generally aggressive 
lymphoid malignancies, accounting for 10-15% of all non-Hodgkin lymphomas. 
Angioimmunoblastic T-cell lymphoma (AITL) represents approximately 20% of all PTCLs 
and is recognized as a distinct entity. Accurate diagnosis and classification of PTCL 
remain challenging. With the exception of ALK+ ALCL, patients with PTCL generally 
have a poor prognosis with standard chemotherapy and even with the availability of 
many novel drugs, including HDAC inhibitor (romidepsin and belinostat), gemcitabine, 
and bortezomib. Therefore, deciphering the pathogenesis of this group of diseases is 
needed to identify novel treatable targets for better therapeutic intervention. The overall 
goal is to study the genetic and epigenetic alterations in PTCL, particularly AITL, to 
improve accuracy of diagnosis and identify novel targets for effective therapy.  
T-cell clonality of PTCL is routinely evaluated with a PCR-based method using 
genomic DNA. However, there are limitations with this approach. To determine the utility 
of RNA-seq for assessing T-cell clonality and TCR repertoire of the neoplastic T-cells in 
PTCL samples, we assessed TCR transcript including complementarity-determining 
region 3 (CDR3) sequences. In normal T cells, the CDR3 sequences are extremely 
diverse, without any clonotype representing more than 2% of the overall TCR population. 
Dominant clones could be identified by transcriptome sequencing in most cases of AITL 
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(36/40), ALCL (18/22), and PTCL-NOS (11/14) with adequate TCR transcript expression. 
In monoclonal cases, the dominant clone varied between 10.9% and 98.9% of TCRβ 
rearrangements. No unique α or β chain usage is observed. RNA-seq is a useful tool for 
detecting and characterizing clonal rearrangements in PTCL.  
We performed targeted resequencing on 92 cases of PTCL and identified 
frequent mutations affecting TET2, DNMT3A, RHOA, and isocitrate dehydrogenase 2 
(IDH2). Whereas IDH2 mutations are largely confined to AITL, mutations of the other 
three can be found in other types of PTCL although at lower frequencies. We correlated 
mutational status with gene expression and global DNA methylation changes in AITL. 
Strikingly, AITL cases with IDH2R172 mutations demonstrated a distinct gene expression 
signature characterized by down-regulation of genes associated with TH1 differentiation 
(e.g., STAT1 and IFNG) and a striking enrichment of an IL12-induced gene signature. 
Ectopic expression of IDH2R172K in the Jurkat cell line and CD4+ T cells led to markedly 
increased levels of 2-hydroxyglutarate, histone-3 lysine methylation, and 5-
methylcytosine and a decrease in 5-hydroxymethylcytosine. Correspondingly, clinical 
samples with IDH2 mutations displayed a prominent increase in H3K27me3 and DNA 
hypermethylation of gene promoters. Integrative analysis of gene expression and 
promoter methylation revealed recurrently hypermethylated genes involved in TCR 
signaling and T cell differentiation that likely contribute to lymphomagenesis in AITL. 
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Chapter 1 Introduction 
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T cell development, selection, and differentiation  
T lymphocytes play a central role in host defense and cell-mediated immunity. The 
immune system must provide specific immunity against a large number of foreign 
antigens and also avoid attacking the self. The processes of T cell differentiation and 
selection satisfy these two needs. 
T cell differentiation includes T cell receptor (TCR) rearrangement and 
expression and co-receptor expression. All T cells originate from hematopoietic stem 
cells in the bone marrow, and their development occurs in the thymus. Hematopoietic 
progenitors from hematopoietic stem cells migrate to the thymus to complete their 
antigen-independent maturation into functional T cells, which require rearrangement of 
their antigen receptor gene loci. There are two types of T cells according to their antigen 
receptor expression: αβ-T cells and γδ-T cells. TCR rearrangement may contribute to 
αβ/γδ lineage decision. TCRδ rearranges first, followed by TCRγ, TCRβ, and then TCRα 
rearrangement. Commitment to γδ lineage occurred before complete TCRβ 
rearrangement. αβ-T cells develop from cells unable to produce functional γδ 
rearrangement. The γδ-T cells migrate to spleen, mucosa, and skin and function in the 
innate-like immune system. The αβ-T cells can further differentiate into CD4+ helper or 
CD8+ cytotoxic T cells and function in the adaptive immune system.  
The selection process includes positive selection for T cells that can interact 
appropriately with self-MHC and negative selection to delete self-reactive T cells. The 
thymic microenvironment directs differentiation as well as positive and negative selection. 
Immature double negative (DN, CD4-/CD8-) thymocytes undergo rearrangement of 
TCRβ chain. Surface expression of TCRβ and pTα form a functional pre-TCR, which 
result in proliferation of DN thymocytes and rearrangement of the TCRα chain. During 
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the process of rapid expansion, DN thymocytes express CD4 and CD8 coreceptors on 
their surface and become double positive (DP, CD4+/CD8+).  Successfully rearranged 
TCRα and TCRβ form a mature TCRαβ receptor, which, together with CD3, is expressed 
on the surface and interacts with peptide presented by MHC on antigen presenting cells. 
DP thymocytes that recognize self-MHC receive a positive selection signal. 
Subsequently, CD4 is down-regulated if the T cell is positively selected on class I MHC, 
and CD8 is down-regulated if the T cell is positively selected on class II MHC. Only 2% 
of the T cells are able to become mature immunocompetent single positive (SP, 
CD4+CD8- or CD4-CD8+) T cells. 
Naïve CD4+ T cells exit from the thymus and can differentiate into one of several 
subtypes of T cells (Th1, Th2, Th9, Th17, Treg, and Tfh). This process is instructed by 
distinct environmental cytokines which up-regulate lineage defining transcription factors 
through signal transducer and activator of transcription (STAT). For instance, Th1 
differentiation is induced by interferon-γ (IFN-γ)/IL-12 through STAT1/STAT4 and T-bet 
(TBX21). Th2 differentiation is induced by IL-4 signaling through STAT6 and GATA3. 
The main role of CD4+ T cells is to secrete cytokines that regulate immune cells. 
Different subsets of CD4+ T cells acquire restricted patterns of cytokine secretion and 
function differently in the adaptive immune system. Th1 cells facilitate cell-mediated 
immune responses to viruses, bacteria, and cancer cells. Th2 cells facilitate anti-parasite 
immunity and antibody responses. Th17 cells enhance immune responses against 
extracellular bacteria and fungi. Treg cells are a CD4+ lineage expressing the master 
transcription factor FoxP3 and negatively regulate immune responses.  
Tfh cells are required for the formation and function of the germinal center (GC), 
which is a specialized microenvironment formed in secondary lymphoid tissues and 
consisting of B cells, Tfh cells, follicular dendritic cells (FDCs), and macrophages. Tfh 
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cells are characterized by their homing capacities to the B-cell follicles after they 
encounter antigens presented by APCs. Tfh cells encounter their cognate B cells and 
regulate their survival and antibody responses. After priming with a dendritic cell (DC), a 
naïve CD4+ T cell may up-regulate CXCR5 and down-regulate CCR7 to migrate to the 
border of B cell follicle and initiate Tfh cell differentiation (Choi et al., 2011). 
Extrafollicular helper T cells expressing CD4 and low amount of CXCR5 and ICOS 
(CXCR5loICOSloCD4+) are exclusively localized outside of GC. They express CXCL13, 
IL-21, and CD40L, but not BCL6. IL-21 production requires IL-12 mediated STAT4 
activation. IL-12 and IL-23 signalings are activated through STAT3 (Schmitt et al., 2014). 
IL-21 is a potent activator of GC B cell differentiation and immunoglobulin isotype 
switching. BCL6 expression is associated with CXCR5 expression in vivo (Choi et al., 
2011). Ectopic overexpression of BCL6 drives further Tfh differentiation (Lu et al., 2011; 
Schmitt et al., 2014), whereas BCL6 deficiency in CD4+ T cells impairs the generation of 
Tfh cells and GC (Nurieva et al., 2009). In addition to BCL6, there are several 
transcriptional factors required for Tfh differentiation. These include Maf, IRF4, and the E 
protein Ascl2 (Bollig et al., 2012; Ise et al., 2011; Liu et al., 2014). Finally, the Tfh cells 
home to the B-cell follicles. There is a bidirectional exchange of signals between GC Tfh 
cells and B cells. B cells serve as APCs and provide ICOS ligand (ICOSL). Tfh cells 
support B cell proliferation and survival by providing CD40L, IL-21, and IL-4. IL-21 
deficiency results in impaired GC formation and inadequate antibody generation (Spolski 
and Leonard, 2008). CD40L stimulation activates DCs, further supporting the activation 
of the T cells. The GC Tfh cells are characterized as CXCR5hiPD1hiBCL6hiMafhiSAPhi. 
Tfh cells show intense interaction with other types of cell and their survivals are 
dependent on the microenvironment, including B cells and FDCs. Development of Tfh 
cells is similar but different between human and moue. For instance, the cytokine TGF-β 
functions together with IL-12 and IL-23 to promote the expression of many Tfh molecules, 
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including CXCR5, IL-21, and BCL6, in human (Schmitt et al., 2014). On the contrary, 
TGF-β signals suppress the expression of Tfh molecules including IL-21, ICOS, and, 
Bcl6, in mouse. Several groups have been trying to culture or induce Tfh cells in vitro. 
Using IL-23 and TGF-β, it is possible to get more than 70% CXCR5+ cells in vitro in 
humans (Schmitt et al., 2014). Using stimulated sorted naïve CD4+ T cells from OT-II 
mice in the presence of mitomycin-treated T cell-depleted splenocytes as APCs and 
neutralizing antibodies against IL-4, IL-12, IFN-γ, and TGF-β, along with IL-6 and IL-21 
in IMDM medium got about 23% PD1+CXCR5+ T-cells in mouse (Lu et al., 2011).   
Although the subsets of helper T cells appear to be phenotypically distinct, there 
is increased recognition of plasticity among them. Many of the lineage markers can be 
broadly expressed on different subsets. For instance, IL-21 is one of the key markers of 
Tfh cells, but can also be produced Th17 and Th1 cells. More importantly, different 
subsets can switch their phenotypes. GATA3+ Th2 cells have been reported to be 
reprogrammed to express Th1 markers, including T-bet and IFN-γ during viral infection 
(Hegazy et al., 2010). Tfh cells appear to be a subset showing most flexibility and can be 
induced to Th1, Th2, or Th17 cells. This plasticity is partially regulated by “epigenetic” 
changes, which are heritable changes in phenotypes without alterations of DNA 
sequences. Gene expression can be regulated by histone modifications, which loosen or 
condense the chromatin structure. Key transcription factors, including TBX21 and BCL6 
can exhibit both repressive and active histone marks, including H3K27me3 and 
H3K4me3, which is a “poised” state. This may explain how subsets of helper T cells can 
be readily induced to other subsets. 
TCR structure and signaling 
As the main effectors of adaptive immunity, T cells utilize TCR to recognize 
various antigens presented by MHC class I or II molecules. Developing T cells employ a 
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series of DNA recombination events to generate an incredibly diverse TCR repertoire. 
The TCR includes the α, β, γ, and δ chains, which form α/β or γ/δ heterodimeric 
receptors that are expressed on the surface of mature T cells. TCRs are specific for 
antigen recognition in conjunction with MHC molecules, leading to activation and 
proliferation of T cells with engagement of CD28.  The variable region domains of α/β or 
γ/δ come together to form the antigen binding cleft. Sequences within several 
complementarity-determining regions (CDRs), particularly CDR3, contribute most to 
TCR specificities.  TCR are incredibly variable, with 1016 to 1018 different possible 
sequences. Diversity of the TCR repertoire reflects the initial V(D)J recombination events 
as shaped by selection by self antigens. The nearly limitless TCR repertoire is generated 
from combinational diversity and junctional diversity. Combinational diversity is due to 
recombination of germline V(D)J segments and possible association between translated 
α chain and β chain. Similar with Immunoglobulin, the V(D)J recombination events of 
TCR are directed by conserved 12 recognition signal sequences (RSSs) or 23 RSSs 
flanking each of the V, D, and J coding elements. The V(D)J recombinase complex, 
which contains RAG-1 and -2, recognize and bind the RSSs, bring them together, and 
form a synaptic complex. Within this complex, RAGs introduce precise double-strand 
breaks between TCR gene segments and RSSs. Following cleavage, the four resulting 
broken ends are held together. Subsequent repair of double-strand breaks by non-
homologous end joining (NHEJ) results in assembly of TCR coding regions and signal 
joints. Further complexity is created by junctional diversity, which is the addition of N-
nucleotides by terminal deoxynucleotidyl transferase and highly random, error-prone 
joining between elements of DNA. V(D)J recombination and addition/deletion of 
nontemplated bases generate hypervariable CDR3 regions, which encode the principal 
site of antigen contact. This hypervariability is crucial for TCR for recognize diverse 
antigens presented by MHC. 
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Binding of TCR to antigen-MHC complex, with appropriate co-stimulatory 
signalings, promote rapid clonal expansion of effector T cells. TCR signaling is initiated 
by the immunological synapses between T cells and antigen-presenting cells where 
MHC/peptide and CD4 or CD8 are bound. TCR alone cannot effectively signal after it 
has bound antigen and has to form TCR complex with the CD3γ, δ, ɛ, and ζ chains. 
Once TCRs and CD4 or CD8 molecules bind to MHC/peptide complexes, Lck is 
activated and subsequently phosphorylates the immunoreceptor tyrosine-based 
activation motifs (ITAM) in the ζ and ɛ chains of the CD3 complex.  ZAP-70 docks at the 
phospholated ITAMs and is then phosphorylated by Lck. The signaling cascade is 
extended by phosphorylating LAT, which is a transmembrane adaptor protein associated 
with Grb2, Gads, and PCLG1 via its four distal tyrosine residues. Finally, with calcium 
mobilization, MAPK signaling and Rho GTPase signaling are activated. 
Peripheral T cell lymphoma (PTCL) and its classification 
Peripheral T-cell lymphomas (PTCLs) and natural killer cell-lymphomas (NKCLs) 
form a heterogeneous group of generally aggressive lymphoid malignancies, accounting 
for approximately 10-15% of all non-Hodgkin lymphomas. This group of diseases is 
uncommon, and the incidence of some of these lymphomas varies depending on the 
geographic location and racial composition. In general, they are more common in Asia 
than in western counties (Vose et al., 2008). According to the current WHO classification, 
PTCLs can be sub-classified, according to locations, into nodal, extra-nodal, cutaneous, 
or leukemic group (Swerdlow SH, 2008). The nodal T cell lymphoma group is the most 
common worldwide and can be further classified into many subtypes based on their 
distinct clinicopathologic differences, including angioimmunoblastic T-cell lymphoma 
(AITL), anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma 
(ATLL). PTCL-not otherwise specified (PTCL-NOS) is the major sub-category (25.9%) 
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worldwide and represents heterogenous PTCL cases that do not meet the criteria for 
other subtypes (Vose et al., 2008). AITL is recognized as the most common specific 
subtype (18.5%) of PTCL with distinct clinical and pathological features. It affects mostly 
middle-aged and elderly individuals, with a slight male predominance. There is strong 
evidence that Tfh cell is the cell of origin; however much about AITL pathogenesis has 
yet to be revealed including the role of EBV, B-cell deregulation, and the 
microenvironment. Clinically, the patients may present with polyclonal 
hypergammaglobulinemia, B symptoms, and various autoimmune phenomena. 
Pathologically, biopsies of lymph nodes from AITL patients show partial or complete 
effacement of the nodal architecture, polymorphous infiltrate with prominent arborizing 
high endothelial venules, and proliferation of FDCs, which are CD21+, CD23+, or CD35+. 
The cancerous cells are usually small to intermediate in size with clear cytoplasm, 
positive for pan-T cells antigens (CD2, CD3, and CD5), and mostly CD4+. Other markers, 
including CD10, CXCL13, PD1, and BCL6, have been used to improve the accuracy of 
diagnosis. Identification of EBV positive infiltrating B cells also facilitates the diagnosis. 
ALCL comprises a group of CD30+ systemic or cutaneous PTCL cases that lacks 
surface expression of a TCR and its associated CD3 complex (Bonzheim et al., 2004). 
There are two distinct groups of systemic ALCL distinguished by the expression of 
anaplastic lymphoma kinase (ALK) protein. ALK+ ALCL has a chromosomal 
translocation involving ALK and nucleophosmin (NPM) or other partners (Morris et al., 
1995), resulting in constitutive ALK tyrosine kinase activity (Morris et al., 1994; Rimokh 
et al., 1989; Zhao et al., 2004). ALK+ ALCL is a more homogeneous group of disease 
and more common in children and young adults, accounting for 10-20% of childhood 
NHL. The 5-year overall survival of ALK+ ALCL patients (70~86%) are better than that of 
ALK- ALCL (30~49%) and other PTCLs. ATLL is a distinct PTCL associated with HTLV-1 
infection and represents a CD4+CD25+ lymphoproliferative disease. ATLL patients 
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usually present with significant immune-suppression and show poor prognosis. It can be 
sub-classified into the acute, lymphoma, chronic, and smoldering types according to the 
clinical features and prognosis of patients. Its clinical symptoms include skin lesions, 
lymphadenopathy, hepatosplenomegaly, and hypercalcemia. The therapeutic strategy is 
based on the clinical subclassification and prognostic factors, including chemotherapy, 
antiviral therapy, allogeneic hematopoietic stem cell transplantation (Tsukasaki et al., 
2009). 
Cellular origin of PTCL 
Understanding the development mechanisms of different subtypes of T cells in 
human is relevant to the pathogenesis of PTCL. The WHO classification is largely based 
on the cell lineage and differentiation stage of the tumor cell and the cellular origin of a 
tumor could be a critical determinant of the tumor biology and clinical behavior. PTCL, 
especially PTCL-NOS, is highly heterogenous. The cell-of-origin (COO) of the different 
entities, aside from AITL, has not be delineated. 
A Tfh-related gene signature was reported in AITL and a subset of PTCL-NOS 
(de Leval et al., 2007; Grogg et al., 2005; Piccaluga et al., 2007). The recent 
identification of Tfh cell as the COO of this neoplasm represents a major step in our 
understanding of the pathobiological characteristics of the disease. Clinically, Tfh-
associated molecules, including CD10, BCL6, PD1, CXCL13, CXCR5, SAP, and ICOS, 
are used to facilitate the diagnosis of Tfh-derived T cell lymphomas. The clinical features 
of AITL are quite distinctive, and the proliferation of FDCs and high endothelial venules 
as well as the almost universal presence of EBV transformed B-cells are also very 
characteristic.  
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Using unsupervised hierarchical clustering of gene expression profiling data, we 
recently identified two novel molecular subgroups within PTCL-NOS showing distinct 
signaling pathways and different prognosis (Iqbal et al., 2014). They are characterized 
by high expression of either TBX21 (Th1 master regulator) or GATA3 (Th2 master 
regulator) and corresponding target genes in both mRNA level and protein level. GATA3 
subgroup defines a high-risk subset of PTCL-NOS and associated with inferior outcome. 
TBX21 subgroup is more heterogenous, as it could be further divided into groups with or 
without a cytotoxic profile. 
Genetic and epigenetic alterations in PTCL 
Cancers are caused by an accumulation of cooperative genomic alterations.  
Several types of PTCL have a tumor-defining abnormality, such as ALK translocation in 
ALCL and HTLV1 integration in ATLL. Other recurrent genetic abnormalities, such as 
rearrangements involving IRF4, DUSP22, SYK, and ITK are infrequent and do not define 
subtypes of PTCLs. Up to 1/4 of ALCL cases show loss at 17p13 and at 6q21, 
encompassing the TP53 and PRDM1 genes, respectively (Boi et al., 2013). 
Mutations in PTCL have been reported in recent years. We and others have 
identified frequent mutations affecting isocitrate dehydrogenase 2 (IDH2) at arginine-172 
(R172), ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), and 
RHOA (G17V) in Tfh-associated PTCL (Cairns et al., 2012; Couronne et al., 2012; 
Odejide et al., 2014; Palomero et al., 2014; Sakata-Yanagimoto et al., 2014). Less 
frequently, mutations affecting CD28, FYN, ATM, B2M, and CD58 have been reported in 
PTCL (Palomero et al., 2014; Rohr et al., 2016). 
RHOA is a small GTPase, linking various cell surface receptors to different 
intracellular signaling pathways. It cycles between an inactive GDP-binding state and an 
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active GTP-binding state. Guanine exchange factors (GEFs) mediate the activation of 
RHOA through GTP loading. G17V mutant RHOA cannot bind to GTP, resulting in 
defective RHOA signaling. 
It has become clear that both genetics and epigenetic changes contribute to 
cancer onsets and progression. Gene transcription is controlled by various mechanisms, 
including lncRNA regulation, promoter methylation, and histone modifications. IDH2, 
TET2, and DNMT3A mutations may all affect epigenetic modifications and emphasize 
the role of epigenetic modifications in PTCL. TET2 and DNMT3A mutations may occur at 
an early stage of hematopoietic cell differentiation, as these mutations have been found 
in non-malignant hematopoietic cells of several PTCL cases and in the hematopoietic 
stem cell of normal elderly individuals (Couronne et al., 2012; Ruggiero et al., 2015; 
Sakata-Yanagimoto et al., 2014; Xie et al., 2014). Loss-of-function mutations of 
DNMT3A have been observed in several hematological malignancies, leading to DNA 
hypomethylation (Li et al., 2013). A growing number of cancers have been found to be 
associated with aberrant DNA methylation. This has provided new and fundamental 
insights into DNA methylation and other epigenetic modifications as potential therapeutic 
targets. 
DNA methylation is the most common DNA modification. DNA methylation at the 
carbon 5 position of cytosine (5mC) represents a heritable epigenetic modification 
associated with transcriptional regulation and genomic stability. In most cells, this 
methylation occurs almost exclusively at CpG dinucleotides, which may form CpG 
islands near gene promoter and these island are generally not methylated. 
Hypermethylation may impair transcriptional initiation and repress gene expression. The 
enzymes that catalyze the addition of a methyl group to cytocine are DNA 
methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b. In the 
demethylation process, a class of alpha-ketoglutarate (α-KG)-dependent dioxygenases, 
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the TET family of proteins, including TET1, 2 and 3, is responsible for the hydroxylation 
and further oxidation of 5mC. Under physiological conditions, 5mC in DNA can be 
converted to 5hmC and then to 5-formylcytocine (5fC) and 5-carboxylcytosine (5caC) by 
TET proteins in the presence of an Fe(II) and α-KG. The modified 5mC can eventually 
be replaced by unmodified cytosine through various DNA repair-based mechanisms. 
However, loss-of-function mutations of the TET family members can impair the 
demethylation process and lead to hypermethylation of CpG sites including normally 
non-methylated CpG islands. Recently, loss-of-function mutations of TET2 have been 
reported to be associated with decreased 5hmC levels in various myeloid malignancies. 
In addition, other prevalent mutations identified in the same study include genes 
encoding cytosolic IDH1 and mitochondrial IDH2, both of which normally catalyze the 
oxidative decarboxylation of isocitrate and produce CO2 and α-KG. Studies in malignant 
gliomas and in myeloid malignancies suggest that the mutations of IDH1/2 result in a 
novel enzymatic activity generating the oncometabolite 2-HG, which is a competitive 
inhibitor of α-KG. Consequently, the mutant IDH1/2 can repress the function of TET 
proteins through 2-HG (Figure 1.1). Therefore, both the loss-of-function mutations in 
TET2 and gain-of-function mutations in IDH1 or -2 can impair the demethylation process 
and consequently result in hypermethylation of CpG islands. 
Challenges for PTCL management 
Due to varied morphology and lack of definitive markers, one of the challenges 
we are still facing is the accurate diagnosis and classification of PTCL. For instance, 
although CD30 is consistently expressed by ALCL, it can not be used as a defining 
criterion. A fraction of PTCL-NOS and AITL can also express CD30 (Onaindia et al., 
2016). Billions of cells in a human body share the same genome but express different 
proteins. The cells in different organs have different tissue specific expression profiles 
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related with specialized functions of the cells. Gene expression of individual cell type can 
be evaluated either at the mRNA or protein level. GEP has been used to improve the 
diagnosis of PTCL and to better understand its pathobiology. Our lab has established 
molecular signatures to classify different subtypes of PTCL based on gene expression 
profiling of a cohort of 372 patients (Figure 1.2). New diagnostic tools and molecular 
genetic markers may be developed to further subdivide PTCL for prognostication and 
more individualized treatment strategy.  
A cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-
like regimen is commonly used for PTCL treatment. But the long-term disease-free 
survivals are unsatisfactory, due to lack of durable responses. Stem cell transplantation 
has been used in PTCL treatments, but the indication and timing of transplantation need 
further investigation. With the exception of ALK+ ALCL, patients with PTCL generally 
have a poor prognosis with standard chemotherapy and even with the availability of 
many novel drugs, including HDAC inhibitor (romidepsin and belinostat), gemcitabine, 
and bortezomib. Therefore, deciphering the pathogenesis of this group of diseases is 
needed to identify novel treatable targets for better therapeutic intervention. Clinical trial 
needs to be performed with a new paradigm where response to an agent will be 
correlated with the molecular characteristics of the tumors and its microenvironment.  
Overview of the chapters 
The overall goal is to study the genetic and epigenetic alterations in peripheral T-
cell lymphomas, particularly AITL, to improve accuracy of diagnosis and identify novel 
targets for effective therapy. 
PTCL is routinely evaluated with a PCR-based method to detect TCRγ chain 
rearrangement using genomic DNA. However, there are limitations with this approach, 
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including the lack of sequence information. In Chapter 2, we took advantage of the fact 
that PTCLs are originated from mature T cells, which have high expression of 
rearranged TCR segments and assessed the clonality and TCR usage in tumor samples 
using V segments and CDR3 sequences extracted from whole transcriptome 
sequencing data.  
IDH2R172, TET2, DNMT3A, and RHOA have been identified as commonly 
mutated in AITL. In addition, we have identified CD28 fusion transcript and mutations by 
whole transcriptome sequencing analysis. In Chapter 3, in order to rapidly identify the 
pattern of mutations and the frequency of the mutated genes in PTCL, we performed 
targeted re-sequencing of IDH2, TET2, DNMT3A, RHOA, and CD28 on 92 PTCL 
samples and gene expression profiling on 37 AITL samples. The IDH2R172 mutations are 
almost exclusively found in AITL. Strikingly, AITL cases with IDH2R172 mutations 
demonstrated a distinct gene expression signature characterized by down-regulation of 
genes associated with Th1 differentiation (e.g., STAT1 and IFNG) and a striking 
enrichment of an IL12-induced gene signature.  
In Chapter 4, we focused on functional study of IDH2R172 mutations in T cells and 
AITL. Ectopic expression of IDH2R172K in the Jurkat cell line and CD4+ T cells led to 
markedly increased levels of 2-HG, histone-3 lysine methylation, and 5mC and a 
decrease of 5hmC. Correspondingly, clinical samples with IDH2 mutations displayed a 
prominent increase in H3K27me3 and DNA hypermethylation of gene promoters. 
Integrative analysis of gene expression and promoter methylation revealed recurrently 
hypermethylated genes involved in TCR signaling and T cell differentiation that likely 
contribute to lymphomagenesis in AITL. 
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In Chapter 5, the major conclusions were summarized and future directions were 
discussed. Chapter 6 and Chapter 7 are materials and methods section and bibliography 
section, respectively. 
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Figures  
Figure 1.1 Gain of function mutation of IDH2 and loss of function mutations of 
TET2 in cancers. 
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Figure 1.2 Molecular signatures of PTCL subgroups. 
  
19	  
	  
 
 
 
 
 
Reprint from (Iqbal et al., 2014) with permission. 
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Chapter 2 Assessment of T-cell receptor repertoire and clonal expansion in 
peripheral T-cell lymphoma using RNA-seq data 
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receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq 
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Summary  
T-cell clonality of peripheral T-cell lymphoma (PTCL) is routinely evaluated with a PCR-
based method using genomic DNA. However, there are limitations with this approach. 
The purpose of this study was to determine the utility of RNA-seq for assessing T-cell 
clonality and repertoire of the neoplastic T-cells TCR usage in PTCL samples. TCR 
transcript including complementarity-determining region 3 (CDR3) sequences were 
assessed. In normal T cells, the CDR3 sequences are extremely diverse, without any 
clonotype representing more than 2% of the overall TCR population. Dominant clones 
could be identified by transcriptome sequencing in most cases of AITL (36/40), ALCL 
(18/22), and PTCL-NOS (11/14) with adequate TCR transcript expression. In 
monoclonal cases, the dominant clone varied between 11.5% and 95.6% of TCRβ 
rearrangements. No unique α or β chain usage is observed. Small T-cell clones are 
often observed in T- and NK-cell tumors in a percentage higher than observed in 
reactive conditions. γ chain expression was very low in cells expressing TCRαβ, but its 
expression level was high and clonality was detected in a TCRγδ expressing tumor. 
NKCL did not express significant levels of TCR Vβ or Vγ genes. RNA-seq is a useful tool 
for detecting and characterizing clonal rearrangements in PTCL.  
Introduction 
Each T-cell clonotype expresses a unique T-cell receptor (TCR). Diversity of the 
TCR repertoire reflects the initial recombination events of noncontiguous variable (V), 
diversity (D), and joining (J) region segments as shaped by selection by self and foreign 
antigens. The TCR repertoire can be abnormal in some dysfunctional contexts, such as 
autoimmune diseases, vaccination, and tumors. TCRγ rearrangement occurs before 
αβ/γδ lineage commitment and TCRβ rearrangement occurs only in the αβ lineage, 
which accounts for approximately 95% of T cell population.  
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Demonstrating clonal TCR rearrangement is an important adjunct in clinical 
diagnostics, and the unique rearrangement is useful in measuring minimal residual 
disease (MRD) for T lymphoid malignancies. The MRD is a crucial prognostic factor for 
the outcome in ALL and has been included in modern risk-classifications in various 
malignancies (Wu et al., 2012). Molecular-based methods for detecting rearranged TCR 
genes can achieve great sensitivity and precision for detection of MRD (Faham et al., 
2012).  
Peripheral T-cell lymphomas (PTCLs), derived from mature T-cells, constitute 
about 10% of non-Hodgkin lymphomas (de Leval et al., 2009). The diagnosis is based 
on clinical, morphological, immunohistochemical, and genetic features. This group of 
cancers is characterized by clonal expansion of T cells and can be further classified to 
many subtypes based on their distinct clinical differences, including PTCL-not otherwise 
specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-
cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma (ATLL). Pathological 
diagnosis remains challenging. TCR specificity is determined by three complimentarity-
determing regions (CDRs), particularly hypervariable CDR3, which includes the V(D)J 
junctions as well as N-nucleotides added by terminal deoxynucleotidyl transferase. 
Analysis of the TCR repertoire is a difficult task since there is a tremendous diversity of 
TCRs, generated from the recombination of TCR gene segments. T-cell clonality is 
conventionally evaluated with PCR-based assays for TCRγ and β chain rearrangements 
using genomic DNA. Multi-parameter flow cytometry can also detect restricted TCRβ 
gene usage and thus imply clonality (Mao et al., 2015; Salameire et al., 2012). Although 
providing a global picture of the repertoire, these approaches can not evaluate a 
complete possibility of rearrangement and are limited by the lack of sequence 
information.  TCR diversity in PTCL has not been fully profiled with high resolution. 
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Recent advances in next generation sequencing (NGS) have enabled us to examine the 
TCR repertoire at single nucleotide resolution (Robinson, 2015).  
NGS is a powerful method for profiling the TCR repertoire and provides a broad 
view of the immune response to different stimuli, such as infection, vaccination, and 
cancer (Ruggiero et al., 2015; Warren et al., 2011). Several different NGS platforms, 
using genomic DNA or cDNA extracted from T cells, have been used for sequencing the 
TCR. RNA-seq is a powerful technology, allowing quantitative measurement of the 
mRNA expression level of genes, isoform discovery, and also identification of mutations. 
The coverage of whole genome RNA-seq is not high but more than enough to detect the 
rearranged CDR3 in lymphoid malignancies.  Extracted TCR sequences directly from 
RNA-seq data have been utilized to profile tissue-resident T cell repertoires (Brown et al., 
2015). 
We report here the utility of RNA-seq in assessing T-cell clonality and in 
analyzing the TCR repertoire in different PTCL subtypes. V segments transcripts and 
CDR3 sequences of four TCR chains were extracted from whole genome RNA-seq data. 
Both clonal expansion and overall TCR repertoire features were evaluated.  
Results  
TCR transcripts can be efficiently detected from RNA-seq data in AITL, PTCL-NOS, 
and some ALCL cases 
We analyzed RNA-seq data from our laboratory and other sources, including 40 
AITL, 35 ALCL, 17 PTCL-NOS, 15 NKCL, one γδ-T cell lymphoma (γδ-TCL), and 6 
ALCL cell lines (Kucuk et al., 2015; Palomero et al., 2014; Rohr et al., 2015; Yoo et al., 
2014) (Table 2.1). Data from normal T cells were obtained from publicly available 
resources (Weinstein et al., 2014). Each V segment of TCR genes was quantified by 
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normalizing to transcripts per million reads (TPM). We only analyzed the cases with 
sequencing length longer than 70bp. Vα and Vβ transcripts were generally abundant in 
normal T cells. Unlike normal tonsillar T-cell populations, multiple small CDR3 clones in 
addition to the presumed neoplastic ones were often observed in tumors which are 
particularly prominent when a limited number of normal infiltrating T-cells are present. To 
avoid mis-identifying such clones as the neoplastic clone when the neoplastic TCR are 
not expressed or a low number of tumor cells are present, we try to derive a threshold 
for TCR transcripts below which the assessment was considered unreliable. Expression 
of Vα and Vβ in NKCL and γδ-TCL is low and likely from infiltrating T cells. Thus, we 
used NKCL and γδ-TCL samples to set the threshold for selecting cases with sufficient 
TCRα and TCRβ expression for subsequent analysis. Cases with lower expression of 
TCRα and TCRβ than NKCL (RPM: TRA<15.82 or TRB<12.21) were excluded (three 
PTCL-NOS, five ALCL cell lines, and 13 ALCL cases; Figure 2.1).  
Clonal configuration of TCR transcripts in AITL and PTCL-NOS 
CDR3 sequences of TCRα and TCRβ were extracted from RNA-seq data using 
MiXCR. We determined clonality by calculating individual V-segment usage and 
identifying CDR3 sequences.  A case was considered having a clonal population if the 
sum of transcripts from the top two CDR3α or CDR3β clones was at least 10 times 
larger than the third highest or >10% of all observed TCRα or β transcripts. Alternatively, 
a case was considered monoclonal if the sum of the top two Vα or Vβ segments was at 
least 10 times larger than the third highest. In AITL and PTCL-NOS cases, these two 
strategies provided generally concordant assessment of monoclonality of TCRα (70.1%) 
and TCRβ (87.4%) (Table 2.2). In a few cases, however, clonality of TCRα and TCRβ 
was discrepant. Some cases showed two clonal transcripts for either Vα or Vβ 
suggesting transcription from biallelic rearrangements.  
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In normal T cells, the CDR3 sequences of α and β chains are extremely diverse, 
without any clonotype representing more than 2% of the overall TCR population (Figure 
2.3). Dominant clones with unique CDR3 sequences were identified in most AITL cases 
(36/40) (Figure 2.3). The abundance of the clonal transcript varied in monoclonal cases 
(11.5% to 95.6% of TCR with Vβ rearrangements) probably reflecting the variable 
fraction of tumor cells. Four cases had polyclonal Vα and Vβ expression probably arising 
from normal T cells. Fusing mutation data and TCR repertoire data will enable the 
investigation of the potential association between them. IDH2, TET2, DNMT3A, and 
RHOA are frequently mutated in AITL (Cairns et al., 2012; Odejide et al., 2014; Sakata-
Yanagimoto et al., 2014; Wang et al., 2015).  Most monoclonal AITL cases (31/36) 
harbor at least one such mutation, whereas most polyclonal cases (3/4) were negative 
(Figure 2.3). Figure 2.4 shows two examples of monoclonal AITL cases and one 
example of polyclonal AITL cases. The two monoclonal cases were validated by 
performing PCR of rearranged γ chains using corresponding genomic DNA. While the 
failure to detect a clonal transcript could be due to failure to transcribe the TCR genes, 
an alternative explanation is low tumor content with levels of the clonal transcripts below 
the detection threshold. However, our definition of the threshold is operational and more 
extensive experience is needed to identify the best threshold for diagnosis. PTCL-NOS 
originates from CD4 or CD8 cells. Most (11/14) PTCL-NOS cases also demonstrated 
dominant clones based on CDR3α and CDR3β sequences (Figure 2.5).   
We also compared the Vβ gene usage of the PTCL clones with the Vβ usage in 
normal T-cell populations. Preferential usage of particular Vβ was similar among naïve T 
cells, Tfh cells, and Teff cells. Vβ segments often used by AITL clones, such as TRBV 
20-1 were also frequently used by normal T-cells (Figure 2.6). The number of PTCL-
NOS cases is low, but the most commonly used Vβ segments, TRBV-19 and TRBV-9, 
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are also commonly used in normal T-cells (Figure 2.7). Thus, we did not detect any 
distinct preferential usage of a Vβ gene in AITL or PTCL-NOS.   
Epstein-Barr virus (EBV) is expressed in up to 80-90% of AITL cases and infects 
intermediated to large B cells in the microenvironment (Weiss et al., 1992). EBV-derived 
transcripts could be readily detected in many samples (24/40). Although CD8+ T cells 
responding to dominant EBV epitopes preferentially express certain TCR-Vβ segments 
(Callan et al., 2000; Vanhoutte et al., 2009), we did not observe any obvious association 
between Vβ usage and EBV infection in AITL or PTCL-NOS.  
Clonal configuration of CDR3α and CDR3β in ALCL 
ALCL comprises a group of CD30+ PTCL that lacks surface expression of a TCR 
and its associated CD3 complex (Bonzheim et al., 2004). Little is known regarding the 
expression of TCR mRNAs in ALCL. Expression of TCRα and TCRβ transcripts varied 
among ALCL samples but was generally low (Figure 2.1); however, we could detect 
clonal CDR3 transcripts in many of the ALCL cases after filtering out cases with low 
transcript levels. To be certain that ALCL tumor cells can indeed express TCR 
transcripts, we examined their expression in ALCL cell lines. Five of six cell lines lacked 
significant expression of TCR mRNA. L82 is ALK-positive and showed clonal CDR3β, 
but no CDR3α expression (Figure 2.8). There is no significant association between 
status of ALK translocation and monoclonal CDR3 (Fisher’s exact test, two-tailed 
P=0.372). Some cases showed expression of only CDR3α or CDR3β. It is unclear why 
surface TCR expression is absent in ALCL despite TCR mRNA expression for both α 
and β chains. Only one transcript was out of frame. The very low expression of CD3γ in 
ALCL may severely reduce TCR surface expression (Haks et al., 1998) (Figure 2.9).  
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Discussion 
In the current study, we evaluated the clonal expansion and TCR repertoire in 80 
PTCL (40 AITL, 23 ALCL, 14 PTCL-NOS, and one γδ-TCL) at the nucleotide level. 
Sufficient V segment transcripts and CDR3 sequences were extracted from RNA-seq 
data. We have not observed any preferential Vβ usage in the tumors examined. 
Distorted TCR-Vα and TCR-Vβ repertoires were observed in AITL, PTCL-NOS and 
some ALCL. Using a criterion that the sum of the sizes of the top two CDR3 clones is 
greater than 10 times that of the third highest, we can diagnose the majority of T cell 
lymphoma cases (82.5% AITL, 69.6% ALCL, and 71.4% PTCL-NOS). 
Some ALCL cases showed expression of only CDR3α or CDR3β. It is unclear 
why surface TCR expression is absent in ALCL despite TCR mRNA expression. For cell-
surface expression, TCR heterodimers must be noncovalently bound to all CD3 subunits 
(Haks et al., 1998; Samelson et al., 1985). In particular, lack of CD3γ severely reduces 
TCR surface expression (Haks et al., 1998). The very low expression of CD3γ in ALCL 
cases and cell line (Figure 2.9) may explain the discrepancy between TCR mRNA level 
and its surface expression. The mechanisms behind the abnormalities in TCR 
expression require further investigations.   
Selection of the most suitable technology to investigate TCR repertoire and T cell 
clonal expansion is crucial. We took advantage of the fact that T cell lymphomas express 
TCR transcripts at high levels and extracted enough reads from RNA-seq data for 
analysis. Multiplex PCR and 5’-rapid amplification of complementary DNA (cDNA) ends 
(RACE) are the two most commonly used methods to study the immune receptor 
repertoires. The multiplex PCR method needs only one PCR step to amplify the CDR3 
regions before library construction, but may result in PCR bias. RACE followed by high-
throughput sequencing is a cDNA-based technology. The CDR3 region is reverse-
transcribed using a primer from the conserved C gene region of the mRNA transcripts. 
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The second primer is added to the cDNA using TdT and cCTP. This method significantly 
decreases PCR bias, but provides information on one or two chains. There are obvious 
advantages of multiplex PCR and RACE methods, including cost-effectiveness and 
deeper coverage.  They can be utilized to study tumor-infiltrating lymphocytes (TILs), 
which are one of the major players in the tumor microenvironment. Several studies have 
shown that TILs are important in the immune response. Higher infiltration with TILs is 
associated with better prognosis in the context of several cancers (Erdag et al., 2012; 
Pages et al., 2010).  Accumulating evidence suggests that tumor-infiltrating T cell 
reactivity to neoantigens has a critical role in clinical cancer immunotherapies. Many 
groups are attempting to establish effective therapies with an adoptive transfer method 
infusing autologous tumor-infiltrating T-cells to target patient-specific neoantigens. 
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Figures  
Figure 2.1 Expression of TRA and TRB in primary T or NK cells, T or NK cell lines, 
and PTCL or NKCL samples. Transcripts embedding CDR3 per million mapped reads 
(RPM) of each sample. The black bar represents the cutoffs of TCR⍺ and TCRβ 
transcripts in tumors.  
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Figure 2.2 Clonal configuration of TCR transcripts in a γδ-TCL sample. 
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Figure 2.3 Clonal configuration of TCR transcripts in AITL.  
Contribution of CDR3α and CDR3β sequences to the TCR repertoire in 10 normal T cell 
sets and 40 AITL samples. Each bar represents an individual clonotype, with red and 
violet showing the first and tenth ranked predominant clonotypes. Grey represents the 
rest of the identified clonotypes in the sample.  
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Figure 2.4 Clonal configuration of TCR transcripts in AITL.  
Examples of monoclonal (A & B) and polyclonal (C) AITL cases with ranked CDR3 
sequences, V segment usage, and spectrum of rearranged γ chains by PCR. (D) 
Frequency of monoclonal cases of AITL. 
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Figure 2.5 Clonal configuration of TCR transcripts in PTCL-NOS. 
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Figure 2.6 Preferential usage of Vβ segments in normal Tfh cells and AITL. 
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Figure 2.7 Preferential usage of Vβ segments in normal CD4+ T cells and PTCL-
NOS. 
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Figure 2.8 Some ALCL cases showed clonal TCR expression at the mRNA level.  
(A) Contribution of CDR3α and CDR3β sequences to the TCR repertoire in 10 normal T 
cell sets, 22 ALCL samples, and one ALCL cell line. (B) Expression of α, β, γ, and δ 
chains of TCR in primary cells, cell lines, and different subtypes of PTCL samples. (C) 
Expression of γ, δ, ε, and ζ chains of CD3 in primary cells, cell lines, and different 
subtypes of PTCL samples. 
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Figure 2.9 A fraction of ALCL cases showed clonal TCR expression at the mRNA 
level.  
(A) Expression of α, β, γ, and δ chains of TCR in primary cells, cell lines, and different 
subtypes of PTCL samples. (B) Expression of γ, δ, ε, and ζ chains of CD3 in primary 
cells, cell lines, and different subtypes of PTCL samples. 
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Table 2.1 List of samples utilized for RNA-seq. 
Sample	  ID	   Subtype	   Read	  Count	  (Millions)	  
AITL-­‐1	   AITL	   57.6	  
AITL-­‐2	   AITL	   69.5	  
AITL-­‐3	   AITL	   62.1	  
AITL-­‐4	   AITL	   68.2	  
AITL-­‐5	   AITL	   62.8	  
AITL-­‐6	   AITL	   66.4	  
AITL-­‐7	   AITL	   74.7	  
AITL-­‐8	   AITL	   67.6	  
AITL-­‐9	   AITL	   114.1	  
AITL-­‐10	   AITL	   62.3	  
AITL-­‐11	   AITL	   68.4	  
AITL-­‐12	   AITL	   76.2	  
AITL-­‐13	   AITL	   67.6	  
AITL-­‐14	   AITL	   93.6	  
AITL-­‐15	   AITL	   96.9	  
AITL-­‐16	   AITL	   91.7	  
AITL-­‐17	   AITL	   59.9	  
AITL-­‐18	   AITL	   72.6	  
AITL-­‐19	   AITL	   61.2	  
AITL-­‐20	   AITL	   54.8	  
AITL-­‐21	   AITL	   115.7	  
AITL-­‐22	   AITL	   117.8	  
AITL-­‐23	   AITL	   102.7	  
AITL-­‐24	   AITL	   126.2	  
AITL-­‐25	   AITL	   110.5	  
AITL-­‐26	   AITL	   109.3	  
AITL-­‐27	   AITL	   108.8	  
AITL-­‐28	   AITL	   84.8	  
AITL-­‐29	   AITL	   101.6	  
AITL-­‐30	   AITL	   98.4	  
AITL-­‐31	   AITL	   108.4	  
AITL-­‐32	   AITL	   128.2	  
AITL-­‐33	   AITL	   128.3	  
AITL-­‐34	   AITL	   110.0	  
AITL-­‐35	   AITL	   128.4	  
AITL-­‐36	   AITL	   103.3	  
AITL-­‐37	   AITL	   95.8	  
AITL-­‐38	   AITL	   79.4	  
AITL-­‐39	   AITL	   95.8	  
49	  
	  
AITL-­‐40	   AITL	   87.7	  
gdTL	   γδ-­‐TCL	   92.9	  
ALCL-­‐1	   ALCL	   43.0	  
ALCL-­‐2	   ALCL	   47.2	  
ALCL-­‐3	   ALCL	   38.6	  
ALCL-­‐4	   ALCL	   54.4	  
ALCL-­‐5	   ALCL	   42.7	  
ALCL-­‐6	   ALCL	   31.7	  
ALCL-­‐7	   ALCL	   39.9	  
ALCL-­‐8	   ALCL	   58.1	  
ALCL-­‐9	   ALCL	   53.7	  
ALCL-­‐10	   ALCL	   42.5	  
ALCL-­‐11	   ALCL	   60.0	  
ALCL-­‐12	   ALCL	   63.4	  
ALCL-­‐13	   ALCL	   64.6	  
ALCL-­‐14	   ALCL	   67.4	  
ALCL-­‐15	   ALCL	   69.0	  
ALCL-­‐16	   ALCL	   28.2	  
ALCL-­‐17	   ALCL	   26.1	  
ALCL-­‐18	   ALCL	   31.7	  
ALCL-­‐19	   ALCL	   32.3	  
ALCL-­‐20	   ALCL	   34.8	  
ALCL-­‐21	   ALCL	   29.6	  
ALCL-­‐22	   ALCL	   32.2	  
ALCL-­‐23	   ALCL	   54.5	  
ALCL-­‐24	   ALCL	   56.2	  
ALCL-­‐25	   ALCL	   57.5	  
ALCL-­‐26	   ALCL	   77.0	  
ALCL-­‐27	   ALCL	   73.5	  
ALCL-­‐28	   ALCL	   66.6	  
ALCL-­‐29	   ALCL	   68.8	  
ALCL-­‐30	   ALCL	   68.7	  
ALCL-­‐31	   ALCL	   68.2	  
ALCL-­‐32	   ALCL	   69.7	  
ALCL-­‐33	   ALCL	   71.7	  
ALCL-­‐34	   ALCL	   67.8	  
ALCL-­‐35	   ALCL	   61.5	  
Fe_PD	   ALCL	  cell	  line	   91.3	  
Karpas299	   ALCL	  cell	  line	   90.6	  
L82	   ALCL	  cell	  line	   95.3	  
MAC1	   ALCL	  cell	  line	   88.1	  
SUDHL1	   ALCL	  cell	  line	   98.3	  
TS	   ALCL	  cell	  line	   93.1	  
50	  
	  
T-­‐cell-­‐1	   Naïve	  CD4+	  T	  cells	   118.3	  
T-­‐cell-­‐2	   Naïve	  CD4+	  T	  cells	   130.9	  
T-­‐cell-­‐3	   Naïve	  CD4+	  T	  cells	   65.2	  
T-­‐cell-­‐4	   Naïve	  CD4+	  T	  cells	   70.4	  
T-­‐cell-­‐5	   Effector	  T	  cells	   104.2	  
T-­‐cell-­‐6	   Effector	  T	  cells	   71.1	  
T-­‐cell-­‐7	   Effector	  T	  cells	   74.1	  
T-­‐cell-­‐8	   Follicular	  helper	  T	  cells	   111.1	  
T-­‐cell-­‐9	   Follicular	  helper	  T	  cells	   118.8	  
T-­‐cell-­‐10	   Follicular	  helper	  T	  cells	   84.5	  
NKCL-­‐1	   NK	  cell	  lymphoma	   97.9	  
NKCL-­‐2	   NK	  cell	  lymphoma	   96.5	  
NKCL-­‐3	   NK	  cell	  lymphoma	   104.1	  
NKCL-­‐4	   NK	  cell	  lymphoma	   88.3	  
NKCL-­‐5	   NK	  cell	  lymphoma	   97.7	  
NKCL-­‐6	   NK	  cell	  lymphoma	   105.6	  
NKCL-­‐7	   NK	  cell	  lymphoma	   97.3	  
NKCL-­‐8	   NK	  cell	  lymphoma	   115.8	  
NKCL-­‐10	   NK	  cell	  lymphoma	   94.0	  
NKCL-­‐11	   NK	  cell	  lymphoma	   102.5	  
NKCL-­‐12	   NK	  cell	  lymphoma	   98.2	  
NKCL-­‐13	   NK	  cell	  lymphoma	   104.1	  
NKCL-­‐14	   NK	  cell	  lymphoma	   97.8	  
NKCL-­‐16	   NK	  cell	  lymphoma	   124.8	  
NKCL-­‐17	   NK	  cell	  lymphoma	   112.6	  
KHYG1	   NK	  cell	  lymphoma	  cell	  line	   79.1	  
NKYS	   NK	  cell	  lymphoma	  cell	  line	   129.4	  
PMIG-­‐NK92	   NK	  cell	  lymphoma	  cell	  line	   96.9	  
PRDM1-­‐NK92	   NK	  cell	  lymphoma	  cell	  line	   99.7	  
NK-­‐cell-­‐1	   Normal	  NK	  cells	   89.7	  
NK-­‐cell-­‐2	   Normal	  NK	  cells	   124.2	  
NK-­‐cell-­‐3	   Normal	  NK	  cells	   112.3	  
PTCL-­‐NOS-­‐1	   PTCL,	  NOS	   66.0	  
PTCL-­‐NOS-­‐2	   PTCL,	  NOS	   66.5	  
PTCL-­‐NOS-­‐3	   PTCL,	  NOS	   64.6	  
PTCL-­‐NOS-­‐4	   PTCL,	  NOS	   65.2	  
PTCL-­‐NOS-­‐5	   PTCL,	  NOS	   60.5	  
PTCL-­‐NOS-­‐6	   PTCL,	  NOS	   62.9	  
PTCL-­‐NOS-­‐7	   PTCL,	  NOS	   66.7	  
PTCL-­‐NOS-­‐8	   PTCL,	  NOS	   83.4	  
PTCL-­‐NOS-­‐9	   PTCL,	  NOS	   67.0	  
PTCL-­‐NOS-­‐10	   PTCL,	  NOS	   68.5	  
PTCL-­‐NOS-­‐11	   PTCL,	  NOS	   116.4	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PTCL-­‐NOS-­‐12	   PTCL,	  NOS	   136.5	  
PTCL-­‐NOS-­‐13	   PTCL,	  NOS	   151.7	  
PTCL-­‐NOS-­‐14	   PTCL,	  NOS	   137.0	  
PTCL-­‐NOS-­‐15	   PTCL,	  NOS	   120.2	  
PTCL-­‐NOS-­‐16	   PTCL,	  NOS	   155.9	  
PTCL-­‐NOS-­‐17	   PTCL,	  NOS	   125.5	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Table 2.2 Clonal assessment based on TCR CDR3 sequences and variable 
segment usage. 
CaseID	  
Domi
nant	  
TCRα
%	  
TCRα	  
CDR3	  
ratio	  
Domi
nant	  
TCRβ
%	  
TCRβ	  
CDR3	  
ratio	  
Clonality	  
based	  on	  
CDR3	  
Vα	  
ratio	  
Vβ	  
ratio	  
Clonality	  
based	  on	  
V-­‐seg	  
CDR3	  &	  
V-­‐seg	  
concord
ance	  
AITL-­‐1	   14%	   4.0	   17%	   4.5	   Monoclonal	   3.1	   4.0	   Polyclonal	   No	  
AITL-­‐2	   31%	   14.2	   42%	   34.4	   Monoclonal	   16.3	   13.3	   Monoclonal	   Yes	  
AITL-­‐3	   15%	   18.6	   3%	   2.7	   Monoclonal	   8.7	   3.0	   Polyclonal	   No	  
AITL-­‐4	   11%	   2.8	   9%	   2.2	   Monoclonal	   2.9	   2.4	   Polyclonal	   No	  
AITL-­‐5	   38%	   17.6	   80%	   97.8	   Monoclonal	   14.8	   112.7	   Monoclonal	   Yes	  
AITL-­‐6	   74%	   26.8	   7%	   2.6	   Monoclonal	   21.3	   2.5	   Monoclonal	   Yes	  
AITL-­‐7	   11%	   14.3	   5%	   6.9	   Monoclonal	   5.4	   4.8	   Polyclonal	   No	  
AITL-­‐8	   33%	   18.9	   9%	   2.4	   Monoclonal	   5.7	   2.7	   Polyclonal	   No	  
AITL-­‐9	   90%	   65.1	   22%	   10.3	   Monoclonal	   2.8	   4.8	   Polyclonal	   No	  
AITL-­‐10	   40%	   10.7	   58%	   88.8	   Monoclonal	   23.8	   35.1	   Monoclonal	   Yes	  
AITL-­‐11	   69%	   115.7	   80%	   165.1	   Monoclonal	   27.6	   38.7	   Monoclonal	   Yes	  
AITL-­‐12	   30%	   10.2	   74%	   170.5	   Monoclonal	   9.7	   38.9	   Monoclonal	   Yes	  
AITL-­‐13	   41%	   12.9	   44%	   122.4	   Monoclonal	   33.6	   15.7	   Monoclonal	   Yes	  
AITL-­‐14	   2%	   2.1	   4%	   5.6	   Polyclonal	   2.6	   2.4	   Polyclonal	   Yes	  
AITL-­‐15	   24%	   10.9	   1%	   2.3	   Monoclonal	   7.5	   2.4	   Polyclonal	   No	  
AITL-­‐16	   14%	   7.9	   29%	   16.7	   Monoclonal	   5.9	   17.2	   Monoclonal	   Yes	  
AITL-­‐17	   9%	   4.5	   5%	   3.8	   Polyclonal	   3.1	   2.3	   Polyclonal	   Yes	  
AITL-­‐18	   29%	   8.9	   73%	   120.9	   Monoclonal	   23.5	   76.5	   Monoclonal	   Yes	  
AITL-­‐19	   58%	   46.0	   37%	   8.2	   Monoclonal	   14.5	   9.3	   Monoclonal	   Yes	  
AITL-­‐20	   21%	   12.7	   47%	   70.3	   Monoclonal	   11.6	   10.3	   Monoclonal	   Yes	  
AITL-­‐21	   71%	   19.8	   95%	   180.3	   Monoclonal	   26.6	   45.4	   Monoclonal	   Yes	  
AITL-­‐22	   36%	   24.1	   21%	   19.7	   Monoclonal	   9.5	   7.9	   Polyclonal	   No	  
AITL-­‐23	   48%	   23.2	   80%	   150.0	   Monoclonal	   5.0	   27.5	   Monoclonal	   Yes	  
AITL-­‐24	   24%	   18.4	   81%	   303.3	   Monoclonal	   6.4	   105.9	   Monoclonal	   Yes	  
AITL-­‐25	   39%	   17.0	   53%	   19.2	   Monoclonal	   8.0	   16.3	   Monoclonal	   Yes	  
AITL-­‐26	   4%	   3.0	   10%	   4.7	   Polyclonal	   5.2	   3.5	   Polyclonal	   Yes	  
AITL-­‐27	   69%	   27.9	   90%	   160.5	   Monoclonal	   14.8	   83.7	   Monoclonal	   Yes	  
AITL-­‐28	   79%	   11.5	   92%	   90.0	   Monoclonal	   5.4	   74.4	   Monoclonal	   Yes	  
AITL-­‐29	   67%	   17.2	   81%	   74.5	   Monoclonal	   14.8	   93.4	   Monoclonal	   Yes	  
AITL-­‐30	   3%	   5.0	   1%	   2.0	   Polyclonal	   3.2	   2.8	   Polyclonal	   Yes	  
AITL-­‐31	   10%	   4.2	   42%	   14.6	   Monoclonal	   3.0	   12.2	   Monoclonal	   Yes	  
AITL-­‐32	   46%	   61.8	   4%	   5.3	   Monoclonal	   13.5	   2.6	   Monoclonal	   Yes	  
AITL-­‐33	   5%	   4.5	   34%	   37.1	   Monoclonal	   2.8	   7.0	   Polyclonal	   No	  
AITL-­‐34	   47%	   24.7	   34%	   7.0	   Monoclonal	   3.9	   22.6	   Monoclonal	   Yes	  
AITL-­‐35	   35%	   5.0	   62%	   36.7	   Monoclonal	   16.2	   17.2	   Monoclonal	   Yes	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AITL-­‐36	   8%	   4.7	   16%	   7.6	   Monoclonal	   3.7	   3.4	   Polyclonal	   No	  
AITL-­‐37	   60%	   29.9	   12%	   3.4	   Monoclonal	   34.0	   3.0	   Monoclonal	   Yes	  
AITL-­‐38	   43%	   63.9	   61%	   44.8	   Monoclonal	   18.5	   20.4	   Monoclonal	   Yes	  
AITL-­‐39	   77%	   103.1	   78%	   124.7	   Monoclonal	   21.8	   45.1	   Monoclonal	   Yes	  
AITL-­‐40	   55%	   34.1	   66%	   71.9	   Monoclonal	   8.7	   50.8	   Monoclonal	   Yes	  
ALCL-­‐1	   98%	   447.5	   99%	   364.0	   Monoclonal	   47.0	   601.5	   Monoclonal	   Yes	  
ALCL-­‐5	   84%	   92.4	   83%	   60.3	   Monoclonal	   80.9	   54.5	   Monoclonal	   Yes	  
ALCL-­‐6	   10%	   5.3	   11%	   3.8	   Monoclonal	   2.7	   3.5	   Polyclonal	   No	  
ALCL-­‐8	   85%	   54.4	   70%	   17.6	   Monoclonal	   29.6	   10.1	   Monoclonal	   Yes	  
ALCL-­‐9	   66%	   3.4	   51%	   3.0	   Monoclonal	   3.2	   3.0	   Polyclonal	   No	  
ALCL-­‐12	   1%	   3.3	   1%	   2.6	   Polyclonal	   2.5	   3.9	   Polyclonal	   Yes	  
ALCL-­‐16	   60%	   24.9	   81%	   105.7	   Monoclonal	   29.6	   217.6	   Monoclonal	   Yes	  
ALCL-­‐17	   67%	   74.5	   80%	   52.3	   Monoclonal	   50.0	   29.4	   Monoclonal	   Yes	  
ALCL-­‐18	   73%	   54.0	   62%	   51.0	   Monoclonal	   139.4	   20.9	   Monoclonal	   Yes	  
ALCL-­‐19	   2%	   3.5	   1%	   3.0	   Polyclonal	   2.3	   2.3	   Polyclonal	   Yes	  
ALCL-­‐20	   37%	   9.9	   18%	   10.5	   Monoclonal	   2.6	   6.0	   Polyclonal	   No	  
ALCL-­‐21	   52%	   83.7	   73%	   147.8	   Monoclonal	   3.3	   30.1	   Monoclonal	   Yes	  
ALCL-­‐23	   24%	   9.1	   56%	   80.5	   Monoclonal	   3.3	   28.3	   Monoclonal	   Yes	  
ALCL-­‐24	   94%	   153.0	   94%	   23.4	   Monoclonal	   4.3	   28.5	   Monoclonal	   Yes	  
ALCL-­‐25	   34%	   43.3	   3%	   4.5	   Monoclonal	   47.2	   2.8	   Monoclonal	   Yes	  
ALCL-­‐26	   4%	   3.0	   69%	   62.0	   Monoclonal	   2.8	   39.0	   Monoclonal	   Yes	  
ALCL-­‐27	   56%	   11.5	   62%	   30.2	   Monoclonal	   17.8	   12.6	   Monoclonal	   Yes	  
ALCL-­‐28	   4%	   3.4	   11%	   5.3	   Monoclonal	   2.3	   5.3	   Polyclonal	   No	  
ALCL-­‐29	   69%	   14.7	   92%	   643.6	   Monoclonal	   455.1	   267.9	   Monoclonal	   Yes	  
ALCL-­‐32	   1%	   2.6	   1%	   2.2	   Polyclonal	   3.2	   2.3	   Polyclonal	   Yes	  
ALCL-­‐34	   3%	   3.4	   1%	   2.4	   Polyclonal	   2.4	   2.3	   Polyclonal	   Yes	  
ALCL-­‐35	   91%	   190.8	   7%	   2.8	   Monoclonal	   128.5	   2.3	   Monoclonal	   Yes	  
L82	   88%	   15.0	   100%	  
1499.
0	   Monoclonal	   3.6	   876.0	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐1	   53%	   19.7	   52%	   59.8	   Monoclonal	   26.9	   11.6	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐2	   14%	   22.6	   3%	   3.7	   Monoclonal	   7.6	   2.5	   Polyclonal	   No	  
PTCL-­‐
NOS-­‐3	   18%	   24.4	   18%	   6.5	   Monoclonal	   8.6	   6.3	   Polyclonal	   No	  
PTCL-­‐
NOS-­‐4	   14%	   25.6	   8%	   4.5	   Monoclonal	   4.5	   3.1	   Polyclonal	   No	  
PTCL-­‐
NOS-­‐5	   7%	   3.9	   8%	   4.5	   Polyclonal	   3.6	   3.9	   Polyclonal	   Yes	  
PTCL-­‐
NOS-­‐7	   20%	   42.5	   20%	   26.2	   Monoclonal	   4.0	   7.8	   Polyclonal	   No	  
PTCL-­‐
NOS-­‐9	   77%	   23.7	   65%	   8.1	   Monoclonal	   21.7	   16.2	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐10	   50%	   155.3	   60%	   97.7	   Monoclonal	   11.1	   27.2	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐11	   95%	   361.4	   89%	   144.2	   Monoclonal	   5.6	   122.7	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐13	   95%	   578.5	   96%	   167.1	   Monoclonal	   60.5	   287.4	   Monoclonal	   Yes	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PTCL-­‐
NOS-­‐14	   3%	   2.3	   5%	   2.5	   Polyclonal	   3.5	   6.1	   Polyclonal	   Yes	  
PTCL-­‐
NOS-­‐15	   42%	   5.8	   46%	   7.4	   Monoclonal	   2.5	   9.9	   Polyclonal	   No	  
PTCL-­‐
NOS-­‐16	   42%	   5.4	   74%	   34.7	   Monoclonal	   7.3	   27.1	   Monoclonal	   Yes	  
PTCL-­‐
NOS-­‐17	   3%	   2.4	   2%	   2.9	   Polyclonal	   2.7	   2.6	   Polyclonal	   Yes	  
T-­‐cell-­‐1	   0%	   2.0	   0%	   2.3	   Polyclonal	   2.1	   2.3	   Polyclonal	   Yes	  
T-­‐cell-­‐2	   0%	   2.0	   0%	   2.0	   Polyclonal	   2.8	   2.4	   Polyclonal	   Yes	  
T-­‐cell-­‐3	   0%	   2.0	   0%	   2.0	   Polyclonal	   2.2	   2.1	   Polyclonal	   Yes	  
T-­‐cell-­‐4	   1%	   2.3	   0%	   2.4	   Polyclonal	   12.7	   3.4	   Monoclonal	   No	  
T-­‐cell-­‐5	   0%	   2.8	   0%	   3.0	   Polyclonal	   2.6	   2.3	   Polyclonal	   Yes	  
T-­‐cell-­‐6	   1%	   2.2	   1%	   2.4	   Polyclonal	   2.6	   2.0	   Polyclonal	   Yes	  
T-­‐cell-­‐7	   0%	   2.3	   0%	   2.4	   Polyclonal	   3.7	   2.8	   Polyclonal	   Yes	  
T-­‐cell-­‐8	   1%	   2.5	   1%	   2.7	   Polyclonal	   3.2	   2.2	   Polyclonal	   Yes	  
T-­‐cell-­‐9	   1%	   2.4	   1%	   2.6	   Polyclonal	   3.5	   2.1	   Polyclonal	   Yes	  
T-­‐cell-­‐10	   2%	   2.9	   2%	   2.4	   Polyclonal	   2.5	   2.4	   Polyclonal	   Yes	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Chapter 3 Mutations affecting epigenetic regulators in AITL and other subtypes of 
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Summary 
Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of peripheral T-cell 
lymphoma (PTCL) with a poor prognosis. We performed targeted resequencing on 92 
cases of PTCL and identified frequent mutations affecting TET2, DNMT3A, RHOA and 
isocitrate dehydrogenase 2 (IDH2). While IDH2 mutations are largely confined to AITL, 
mutations of the other two can be found in other types of PTCL although at lower 
frequencies. These findings indicate a key role of epigenetic regulation in the 
pathogenesis of AITL. However, the epigenetic alterations induced by these mutations 
and their role in AITL pathogenesis are still largely unknown. Strikingly, AITL cases with 
IDH2R172 mutations demonstrated a distinct gene expression signature characterized by 
down-regulation of genes associated with Th1 differentiation (e.g., STAT1 and IFNG) 
and a striking enrichment of an IL12-induced gene signature.  
Introduction 
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of generally 
aggressive lymphoid malignancies, accounting for 10-15% of all non-Hodgkin 
lymphomas (NHLs) (Vose et al., 2008). Angioimmunoblastic T-cell lymphoma (AITL) 
represents 20-25% of all PTCLs and is recognized as a distinct entity (Federico et al., 
2013; Vose et al., 2008). Currently used chemotherapy is rarely curative with a 5-year 
overall survival of less than 30% (Armitage, 2012; de Leval et al., 2010; 2008). Gene 
expression profiling (GEP) and pathological analysis suggest that the follicular helper T-
cell (Tfh cell) is the cell of origin for AITL (de Leval et al., 2007; Grogg et al., 2005; 
Piccaluga et al., 2007).  
We and others have identified frequent mutations affecting isocitrate 
dehydrogenase 2 (IDH2) at arginine-172 (R172), ten-eleven translocation 2 (TET2), 
DNA methyltransferase 3A (DNMT3A), and RHOA in AITL (Cairns et al., 2012; 
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Couronne et al., 2012; Odejide et al., 2014; Palomero et al., 2014; Sakata-Yanagimoto 
et al., 2014). IDH2, TET2, and DNMT3A mutations may all affect epigenetic 
modifications. TET2 and DNMT3A mutations seem to occur at an early stage of 
hematopoietic cell differentiation, as these mutations have been found in non-malignant 
hematopoietic cells of several PTCL cases and in normal elderly individuals (Couronne 
et al., 2012; Ruggiero et al., 2015; Sakata-Yanagimoto et al., 2014; Xie et al., 2014). 
Loss-of-function mutations of DNMT3A have been observed in several hematological 
malignancies, leading to DNA hypomethylation (Li et al., 2013). Mitochondrial IDH2 
protein and cytosolic IDH1 protein are homologues. Surprisingly, unlike other 
malignancies (Mardis et al., 2009; Yan et al., 2009), AITL harbors mutations only at 
IDH2R172, but not at IDH2R140 or in IDH1. In the tricarboxylic acid cycle, IDH3 catalyzes 
the oxidative decarboxylation of isocitrate to α-KG. Under anabolic conditions, IDH2 
primarily catalyzes the reverse reaction, reductive carboxylation of α-KG to isocitrate. 
The IDH2R172 mutation confers a neomorphic activity—namely, conversion of α-KG to 
the R-enantiomer of 2-hydroxyglutarate (R-2-HG) (Guilhamon et al., 2013), which, in 
normal cells, is maintained at low concentrations by 2-HG dehydrogenases. R-2-HG acts 
as a competitive antagonist of the α-KG-dependent dioxygenases (Xu et al., 2011), 
which notably include the TET family of 5-methylcytosine hydroxylases and jumonji-C 
domain-containing histone demethylases (JHDMs) (Chowdhury et al., 2011; Loenarz 
and Schofield, 2008; Xu et al., 2011).	  Thus, mutant IDH2R172 is predicted to impair DNA 
and histone demethylation and to lead to abnormal regulation of gene transcription, 
which may promote lymphomagenesis. 
The epigenetic alterations induced by IDH2, TET2, and DNMT3A mutations and 
their roles in AITL pathogenesis are still largely unknown. In this study, we performed 
targeted re-sequencing of these three epigenetic regulators in molecularly defined PTCL 
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cases and analyzed alterations in GEP to improve our understanding of their roles in the 
pathogenesis of PTCL. 
Results 
Mutations affecting epigenetic regulators are more frequent in AITL than other 
subtypes of PTCL 
The advent of next generation sequencing techniques has profoundly changed 
the scope and comprehensiveness of genomic studies. Recent whole exome 
sequencing and whole transcriptome sequencing of PTCL cases provided valuable 
information about the mutational landscape of the disease. However, comprehensive 
understanding remains elusive due to limited sample size. Targeted re-sequencing 
focuses on only a selected set of genes and therefore serves as a more cost-effective 
and focused strategy to screen somatic variants in a large series of samples. Here, we 
performed targeted resequencing on 92 cases of PTCL and identified frequent mutations 
affecting IDH2, TET2, DNMT3A, and RHOA. 
Consistent with our previous report (Cairns et al., 2012), mutations in AITL were 
observed in IDH2 at R172, but not at R140, unlike in other cancers. The overall 
frequency of IDH2R172 mutations in AITL was 32.8% (19/58), including cases from our 
previous cohort (Cairns et al., 2012) (Figure 3.1A). In contrast, the IDH2R172 mutation 
occurred in only 1 of 17 PTCL, not otherwise specified (PTCL-NOS) cases, which was 
molecularly classified into the TBX21 subgroup by GEP analysis (Iqbal et al., 2014). The 
most common mutant variants were arginine to serine or lysine, similar to the IDH2 
mutational spectrum in AML. There was no difference in IDH2 mRNA expression levels 
between the IDH2R172 mutant and wild-type cases (Figure 3.2). Unlike the findings in 
AML, where IDH2 mutations are associated with a poor prognosis (Beguelin et al., 2013; 
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Malumbres et al., 2008), no association of IDH2 mutations with overall survival (OS) was 
observed (Figure 3.3A).  
TET2 mutations were found in 82.1% (32/39) of AITL, 46.3% (19/41) of PTCL-
NOS, and 33.3% (4/12) of ALK- ALCL (Figure1A and Table 1.1). In PTCL-NOS, both the 
TBX21 (57%, 10/18) and GATA3 subgroups (41.7%, 5/12) harbored TET2 mutations. 
The TET2 mutations were distributed throughout the entire coding region; however, the 
majority of mutations were observed in the catalytic domains, including the Cys-rich and 
DSBH domains (Delhommeau et al., 2009), with a few recurrently targeted codons 
(Figure 3.1B). We observed DNMT3A mutations at similar frequencies in AITL (38.5%, 
15/39) and PTCL-NOS (36.6%, 15/41), but less frequently in ALK- ALCL (16.7%, 2/12). 
In PTCL-NOS, 33.3% (6/18) harbored DNMT3A mutations in the TBX21 subgroup and 
25% (3/12) in the GATA3 subgroup (Figure 3.1A). Most DNMT3A mutations were 
clustered in the MTase-binding domain (Figure 3.1B), presumably leading to loss of 
function. Of note, the most frequent mutation site was residue Arg-882 (R882) located in 
the MTase-binding domain. This DNMT3AR882 mutant has been reported to inhibit wild-
type DNMT3A activity by disrupting homotetramerization (Lu et al., 2013). 
Sequencing analysis also revealed that some PTCL cases carried more than one 
mutation of TET2 or DNMT3A per tumor (Table 3.1), suggesting that both alleles could 
be mutated and total silencing of these genes may be present in some tumors. None of 
these mutations showed any association with overall survival in AITL or other subtypes 
of PTCL, whether analyzed individually or in combination with one another (Figure 3.3B-
D). While analyzing the variant allele frequency (VAF) of TET2 and DNMT3A mutations, 
we observed that subclonal mutants were relatively frequent in AITL. Because the 
majority of mutations affecting DNMT3A and TET2 are heterozygous and the tumor 
content of PTCL biopsies is varied, we arbitrarily used 10% VAF as a cutoff for the major 
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clone and defined ones with equal or higher than 3% VAF but lower than 10% VAF as 
minor clones. Overall, 73% (46 of 63) of TET2 mutations were observed as a major 
clone [27 of 35 SNVs and 19 of 28 insertions/deletions (indels)], suggesting that TET2 
mutation is crucial in disease pathogenesis. In contrast, only 46% (22 of 48) of DNMT3A 
mutations were observed as a major clone (9 of 22 SNVs and 2 of 3 indels) (Figure 
3.1A).  
The majority (26/29) of RHOA mutations observed in PTCL occurred at the same 
codon, resulting in a Gly17Val substitution in the GTP-binding domain. Consistent with 
previous reports (Sakata-Yanagimoto et al., 2014; Yoo et al., 2014), RHOA mutations 
were very common in AITL (28/39), also present in PTCL-NOS (11/41), but absent in 
ALCL (0/12) (Figure 3.1A) and tended to co-occur with TET2 mutations (two-tailed 
Fisher`s exact test, P = 0.012) and IDH2 mutations (two-tailed Fisher`s exact test, P = 
0.003). All IDH2/TET2 double-mutant AITL cases had a RHOA mutation. 
Interestingly, IDH2 and TET2 mutations were not mutually exclusive, unlike in 
AML or glioblastoma, but showed significant (P < 0.001) co-occurrence in AITL (Figure 
3.1A). Most IDH2 (68%) and DNMT3A (80%) mutant cases also had TET2 mutations.  
IDH2R172 mutations define an AITL subgroup with a distinct gene expression 
signature 
To gain an overview of the functional consequences of the mutations affecting 
epigenetic regulators, we first performed unsupervised hierarchical clustering of 37 AITL 
samples with GEP data and known mutational status of IDH2, TET2, and DNMT3A. 
Interestingly, most IDH2R172 mutant cases formed a single cluster in unsupervised 
hierarchical clustering analysis (Figure 3.4A). We used Fisher's exact test to determine 
the significance of the tendency of neighboring cases on the dendrogram to have 
identical mutation status. The fraction of IDH2R172 mutant cases that had mutant 
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neighbors was significantly higher than the fraction of IDH2 wild-type cases that had 
mutant neighbors (P = 0.011). In contrast, neither TET2 mutant cases (P = 0.073) nor 
DNMT3A mutant cases (P = 0.727) showed significant clustering (Figure 3.4A), 
indicating that IDH2R172 mutations are associated with a unique gene expression profile 
in AITL.  
To identify the genes that are differentially expressed between IDH2 wild-type 
and mutant groups, we performed supervised hierarchical clustering using a univariate 
permutation test for the significance of individual genes (P = 0.001). Among the 344 
differentially expressed genes, approximately 40% (136/344) were downregulated in 
IDH2R172 mutant cases compared to IDH2 wild-type cases, an observation distinct from 
AML (Figure 3.5A) (Marcucci et al., 2010). Only a small subset of genes was 
downregulated in IDH2 mutant cases in both AITL and AML (Figure 3.5B), suggesting 
different functional consequences of IDH2 mutations in these two malignancies. 
Since mutant IDH2 generates 2-HG and consequently can inhibit TET2 enzyme 
activity, IDH2 mutation is not expected to co-occur with TET2 mutation; nevertheless, 
most IDH2R172 mutant cases in AITL also harbor a TET2 mutation (30/36). Therefore, we 
performed class comparison among IDH2/TET2 double-mutant, TET2 single-mutant, 
and wild-type AITL cases to identify the differences among these groups and found 1035 
differentially expressed genes. The tumor cell content of TET2 single-mutant AITL and 
IDH2/TET2 double-mutant AITL was similar (Figure 3.6). Wild-type cases and TET2 
single-mutant cases are similar, but markedly different from IDH2 /TET2 double-mutant 
cases. Double-mutant cases showed upregulation of Tfh-associated genes (IL21 and 
ICOS), and downregulation of genes associated with Th1 (IL2, STAT1, and CXCR3), 
Th2 (IL10RA) and Th17 (IL17RA), indicating a more Tfh cell-like phenotype (Figure 3.4). 
To gain further biological insight, we performed Ingenuity pathway analysis (IPA) and 
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identified several important clusters of genes associated with proliferation, apoptosis, 
cell cycle, and T-cell development and differentiation. Pathways involved in T helper cell 
differentiation, IL-17 signaling (IL17RA, AKT3, CXCL10 and CCL2), and Interferon (IFN) 
signaling (IFNG, STAT1, IFITM3, IRF1, and IFIT3) were dysregulated in IDH2/TET2 
double-mutant cases (Figure 3.7). Strikingly, IPA upstream analysis predicted activation 
of the VEGF pathway and inhibition of IFN signaling in the double-mutant group (Figure 
3.7B). This observation was further supported by GSEA using the Broad Institute and 
lymphoid signature databases, which showed significant enrichment of IFN response 
genes (P < 0.01) in the TET2 single-mutant group (Figure 3.8). However, the double-
mutant cases showed enrichment of EZH2 targets, MYC targets, FOXP3 targets, 
downregulated FOXO3 target genes, and genes associated with proliferation and cell 
cycle transitions or in apoptosis due to CDKN1 via TP53 (Figure 3.7C).  
Compared to wild-type cases, IDH2R172 mutant AITL cases more closely resemble 
normal Tfh cells in gene expression 
We also observed a striking correlation of the GEP of IDH2/TET2 double-mutant 
cases with that of primary CD4+ T cells treated with IL-12 (Figure 3.9). IL-12 is a major 
driver of Tfh cell differentiation, and it can induce naïve CD4+ T cells to differentiate into 
Tfh-like cells in vitro (Schmitt et al., 2009). We analyzed 6245 genes that were highly 
expressed (top quartile) in primary CD4+ T cells either after 48h IL-12 treatment and/or 
no treatment. Among these 6245 genes, the differences in GEP between individual 
double-mutant cases and the median tumor value strongly correlated with the changes 
in GEP induced in normal CD4+ T-cells by IL-12 (Figure 3.11A).  
 To investigate the similarity between double-mutant AITL and primary Tfh cells, 
we utilized transcriptome sequencing data of Tfh cells (n = 3), naïve CD4+ T cells (n = 4) 
and non-Tfh effector cells (n = 3) from a published dataset (Weinstein et al., 2014). By 
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identifying genes with significantly different expression (P ≤ 0.05, one-sided Student’s t 
test) between Tfh cells and both naïve CD4+ T cells and non-Tfh effector cells, we 
defined 1045 “Tfh-up genes” and 699 “Tfh-down genes”. Similar numbers of “Tfh-up 
genes” were upregulated (comparing individual cases to the median expression level) in 
all three mutation groups, but significantly more “Tfh-down genes” were downregulated 
in IDH2/TET2 double-mutant AITL than wild-type and TET2 single-mutant cases (Figure 
3.11B). This suggests that mutant IDH2 is associated with the repression of non-Tfh 
differentiation genes, presumably through epigenetic mechanisms. 
Discussion  
The aberrant DNA and histone methylation identified in various malignancies 
suggests an important role for these epigenetic changes in tumorigenesis, although the 
profiles vary among tumors, indicating a possible dependency on cellular context. 
Mutations of epigenetic regulators (IDH2R172, TET2, and DNMT3A) are common in AITL, 
emphasizing the importance of aberrant epigenetic alterations in lymphomagenesis. 
Given the presence of TET2 and DNMT3A mutations in other subtypes of PTCL, but not 
IDH2R172 mutations, it is highly likely that IDH2R172 mutations play a unique role in the 
pathogenesis of AITL. Indeed, unsupervised hierarchical clustering identified a distinct 
GEP associated with IDH2R172 mutations in AITL. The changes in GEP in IDH2R172 
mutant cases likely resulted in part from promoter hypermethylation, but also from 
disruption of histone lysine demethylation. 
One of the most interesting characteristics in the IDH2/TET2 double-mutant 
group is enrichment of the Tfh-like phenotype and downregulation of features of other 
types of helper T-cells. IL-6, IL-12 and IL-23 have been shown to induce IL-21 
expression in human naïve CD4+ T cells. IL-12 not only can induce IL-21 production but 
also can induce other Tfh phenotypes, including upregulation of CXCR5, ICOS, and 
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BCL6 and the capacity to facilitate B cell differentiation into antibody-secreting cells 
(Wolfe et al., 2014). Treatment of normal human CD4+ T cells by IL-12 for 48 hours 
induced a steady increase of IL-21 and CXCR5. The GEP of IDH2/TET2 double-mutant 
AITL was highly enriched in the signature of CD4+ T cells stimulated by IL-12, 
suggesting a more polarized Tfh phenotype. In addition, IDH2/TET2 double-mutant AITL 
showed similarity of gene expression with primary Tfh cells. These observations suggest 
that limiting the plasticity of differentiation to other Th lineages is an important 
consequence of IDH2R172 mutations. Of the signaling pathways attributable to 
differentiation of helper T-cells, IFN signaling (STAT1, IRF1, and IFIT3) and IL-17 
signaling (IL17RA, CXCL10, and CCL2) were downregulated in the IDH2/TET2 double-
mutant group. Conversely, TGF-β signaling, which contributes to the differentiation of 
TFH cells (Lin et al., 2016a), was enriched.  
 Unlike in AML, IDH2 and TET2 mutations are not mutually exclusive in AITL. 
Despite the significant differences between IDH2/TET2 double-mutant AITL and normal 
tissues, and between TET2 single-mutant AITL and normal tissues, there is only a 
moderate difference in genome-wide methylation (as will be described below in Chapter 
4) between IDH2/TET2 double-mutant and TET2 single-mutant AITL, which seems 
insufficient to explain the much greater differences on GEP. However, GEP includes 
secondary changes from genetic and epigenetic alterations. The significant changes in 
gene expression in the IDH2R172 mutant group may also represent consequences of 
histone modification.  
In AML, both R140 and R172 neomorphic mutants of IDH2 were identified. In 
contrast, AITL harbors mutations only at IDH2R172, but not at IDH1R132 or IDH2R140. This 
exclusivity is highly interesting, but the reason is currently not clear. Studies by others 
have shown that mutations differ quantitatively in 2HG production (Lu et al., 2013; Ward 
et al., 2013); this raises the possibility that different tumor types may favor certain ranges 
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of 2HG concentrations. In previous studies (Lu et al., 2013; Ward et al., 2013), IDH2R140 
was shown to be a weaker 2HG-producing mutant than IDH2R172. In addition, IDH2R172K 
mutant 10T mesenchymal progenitor cells, but not IDH2R140Q mutant cells, can grow as 
xenografts (Lu et al., 2013), indicating different biological consequences resulting from 
the two mutants. In AML, IDH2R140 mutant AML cells frequently have normal 
cytogenetics and NPM1 mutations, but IDH2R172 is frequently the only mutation detected 
(Rakheja et al., 2012), again suggesting biological differences. Understanding the 
mechanistic difference between the IDH2R140 and IDH2R172 mutants is certainly important 
and should be investigated further in the future.  
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Figures 
Figure 3.1 Mutational profiles of IDH2, TET2, DNMT3A and RHOA in patients with 
peripheral T-cell lymphomas. 
(A) Co-occurance of IDH2R172, TET2, DNMT3, and RHOA mutations in patients with 
AITL (n = 39), subgroups of PTCL-NOS (n = 41) and ALK (-) ALCL (n = 12). White color 
indicates wild-type cases. Grey color indicates cases with variant allele frequency (VAF) 
of at least 3% but lower than 10%. Black color indicates cases with VAF of at least 10%. 
(B) Mutations occur in functional domains of the TET2 and DNMT3A proteins. Missense 
mutations, nonsense mutations and insertion/deletions are indicated.  
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Figure 3.2 Expression level of IDH2, DNMT3A, and TET2 in AITL samples with high 
tumor content.  
Expression levels are the average values of different probes in Affymetrix HG-U133-plus 
2.0 arrays. Mutant cases have variant allele frequency equal or higher than 10%. (A) 
IDH2 probesets include 210045_at and 210046_s_at. IDH2 wild-type (n = 7) and 
IDH2R172 mutant cases (n = 10) were utilized. (B) TET2 probesets include 227624_at, 
235461_at and 1569385_s_at. TET2 wild-type (n = 4) cases and TET2 mutant cases (n 
= 13) were utilized. (C) DNMT3A probesets include 222640_at, 244428_at and 
218457_s_at. DNMT3A wild-type (n = 11) and IDH2 mutant cases (n = 6) were utilized.  
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Supplemental Figure 2. Expression level of IDH2, DNMT3A and TET2 in AITL samples with high tumor content. 
Expression levels are the average values of different probes in Affymetrix HG-U133-plus 2.0 arrays. Mutant cases have 
variant allele frequency equal or higher than 10%. (A) IDH2 probesets include 210045_at and 210046_s_at. IDH2 wild-type 
(n = 7) and IDH2R172 mutant cases (n = 10) were utilized. (B) TET2 probesets include 227624_at, 235461_at and 
1569385_s_at . TET2 wild-type (n = 4) cases and TET2 mutant cases (n = 13) were utilized. (C) DNMT3A probesets 
include 222640_at, 244428_at and 218457_s_at. DNMT3A wild-type (n = 11) and IDH2 mutant cases (n = 6) were utilized.  
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Figure 3.3 Association of IDH2, TET2 and DNMT3A mutations with overall survival 
(OS) of AITL patients. 
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Supplemental Figure 3. Association of IDH2, TET2 and DNMT3A mutations with overall survival (OS) of AITL patients.  
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Figure 3.4 IDH2R172 mutations define a unique subgroup of AITL with distinct gene 
expression. 
(A) Dendrogram of unsupervised hierarchical clustering of 37 AITL cases with mutational 
status of IDH2R172, TET2, and DNMT3A. The branches indicate Pearson's correlation 
among the samples. Fisher's exact test was performed to determine the significance of 
the tendency of neighboring cases on the dendrogram to have identical mutation status. 
(B) Supervised heat map of samples across 1035 genes differentially expressed among 
IDH2/TET2 double-mutant (n = 12), TET2 single-mutant (n = 18) and wild-type (n = 6) 
AITL (univariate permutation test, P < 0.01). The profile on the left shows gene 
expression in primary CD4+ T cells treated with IL-12 with 0h, 2h, 8h, 24h and 48h. Each 
column represents a case. Green and red color scale indicates row z-score. Selected 
differentially expression genes are listed at the right side of the profile.  
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Figure 3.5 Genes are differentially expressed in IDH2 wild-type and IDH2R172 
mutant AITL.  
(A) Supervised analysis identified genes that are differentially expressed in IDH2 wild-
type and IDH2R172 mutant AITL (univariate permutation test, P = 0.001). (B) Comparision 
of the IDH2 mutation-related differential expression between AITL and cytogenetically 
normal-AML (Marucci et al, 2010) among genes that are differentially expressed in IDH2 
mutant AITL.  
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Supplemental Figure 4. Genes are differentially expressed in IDH2 wild-type and IDH2R172 mutant AITL.  
(A) Supervised analysis identified genes that are differentially expressed in IDH2 wild-type and IDH2R172 mutant AITL (univariate  
permutation test, P = 0.001 ). (B) Comparision of the IDH2 mutation-related differential expression between AITL and CN-AML  
(Marucci et al, 2010) among genes that are differentially expressed in IDH2 mutant AITL.  
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Figure 3.6 Variant allele frequency (VAF) of RHOA mutations in TET2-single 
mutant and IDH2/TET2 double-mutant AITL cases.  
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Supplemental Figure 5. Variant allele frequency (VAF) of RHOA mutations in TET2-single mutant and IDH2/TET2 double-mutant  
AITL cases. VAF of RHOA mutations were utilized to compare the tumor content between double- and single-mutant groups. All IDH2/TET2  
double-mutant AITL and more than half of TET2 single-mutant AITL (13/25) had RHOA mutations. When more than one mutation found in a  
case, the higher VAF was utilized. The comparison of RHOA mutation VAF indicated the tumor cell content was similar between IDH2/TET2  
double-mutant and TET2 single-mutant AITL.  
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Figure 3.7 Functional annotation of differentially expressed genes between 
IDH2/TET2 double-mutant AITL and TET2 single-mutant AITL. 
(A) Selected top IPA canonical pathways differing between IDH2/TET2 double-mutant 
AITL and TET2 single-mutant AITL. (B) IPA upstream analysis to predicted activation 
state of annotated proteins. “Vegf” and “Interferon alpha” are groups of proteins instead 
of single molecules. Activation z-score > 3 was considered as significant. (C) Apoptosis 
pathway identified by GSEA analysis significantly altered in IDH2/TET2 double-mutant 
AITL compared with TET2 single-mutant AITL. The normalized enrichment score (NES), 
P value, and FDR value are indicated.  
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Figure 3.8 Components in IFN response signaling were dysregulated in IDH2/TET2 
double-mutant AITL compared with TET2 single-mutant AITL.  
Green indicates down-regulation in IDH2/TET2 double-mutant AITL compared with 
TET2 single-mutant AITL. Grey indicates up-regulation in IDH2/TET2 double-mutant 
AITL compared with TET2 single-mutant AITL. The network was generated by IPA and 
modified using Adobe Illustrator. 
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  Supplemental Figure 7. Components in IFN response signaling were dysregulated in IDH2/TET2 double-mutant AITL compared with  
TET2 single-mutant AITL. Green indicates down-regulation in IDH2/TET2 double-mutant AITL compared with TET2 single-mutant AITL.  
Grey indicates up-regulation in IDH2/TET2 double-mutant AITL compared with TET2 single-mutant AITL. The network was generated from  
IPA and modified using Adobe Illustrator. 
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Figure 3.9 IL-12 treatment induced follicular helper T cell phenotypes in primary 
CD4+ T cells.  
(A) IL-12 stimulation induced upregulation of IL-21. (B) IL-12 stimulation induced 
upregulation of CXCR5. (C) IL-12 stimulation induced upregulation of ICOS. (D) IL-12 
stimulation induced upregulation of PD-1. Five sets of CD4+ T cells were treated with IL-
12 for 0, 2, 8, 24, or 48 hours. 
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Supplemental Figure 9. IL-12 treatment induced follicular helper T cells phenotypes on primary CD4+ T cells.  
(A) IL-12 stimulation induced upregulation of IL-21. (B) IL-12 stimulation induced upregulation of CXCR5.  
(B) (C) IL-12 stimulation induced upregulation of ICOS. (D) IL-12 stimulation induced upregulation of PD-1. Five sets of CD4+ T cells  
(C) were treated with IL-12 for 0, 2, 8, 24, or 48 hours. 
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Figure 3.10 Expression of IL-21, ICOS, and STAT1 in AITL and PTCL-NOS cases. 
Expression levels are the values of probes in Affymetrix HG-U133-plus 2.0 arrays. Data 
are shown as mean ± SEM. P value was calculated using the two-tailed Student’s t test. 
* indicates P < 0.05, ** indicates P <0.01. 
  
85	  
	  
 
 
 
 
 
 
  
A B 
C 
Supplemental Figure 6. Expression of IL-21, ICOS, and STAT1 in AITL and PTCL-NOS cases. Expression levels are the values of  
probes in Affymetrix HG-U133-plus 2.0 arrays. Data are shown as mean ± SEM. P value was calculated using the two-tailed Student’s t test.  
* indicates P < 0.05, ** indicates P <0.01. 
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Figure 3.11 Functional annotation of differentially expressed genes between 
IDH2/TET2 double-mutant AITL and TET2 single-mutant AITL. 
(A) Correlations between (1) the differences in GEP between each individual AITL case 
and the median tumor value with (2) the changes in GEP induced in normal CD4+ T-cells 
by IL-12 (48 h). (B) Comparison of the number of “TFH-up genes” and “TFH-down genes” 
(see text) in AITL. Data are shown as mean ± SEM. P value was calculated using the 
two-tailed Student’s t test. * indicates P < 0.05, ** indicates P <0.01, *** indicates P < 
0.001 and **** indicates P < 0.0001. 
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Tables 
Table 3.1 Targeted re-sequencing of TET2 and DNMT3A in PTCL cases. 
Gene  Case  Diagnosis 
Muta
tion 
Nucleotide 
Change 
Amino Acid 
Change 
PolyPhen 
Prediction VAF 
DNMA3A Case1 AITL SNV c.385A>G p.SER129PRO probably-damaging 0.0326 
DNMA3A Case10 PTCL,NOS SNV c.2053C>T p.GLY685ARG probably-damaging 0.3229 
DNMA3A Case11 PTCL,NOS SNV c.1175T>C p.GLU392GLY benign 0.0361 
DNMA3A Case14 AITL SNV c.1996A>T p.CYS666SER benign 0.0303 
DNMA3A Case18 PTCL,NOS SNV c.1051A>G p.CYS351ARG benign 0.0314 
DNMA3A Case18 PTCL,NOS SNV c.412T>C p.THR138ALA benign 0.0359 
DNMA3A Case21 AITL SNV c.1514T>C p.GLU505GLY benign 0.034 
DNMA3A Case21 AITL SNV c.1051A>G p.CYS351ARG benign 0.0314 
DNMA3A Case22 N.A SNV c.2659T>C p.ARG887GLY possibly-damaging 0.0353 
DNMA3A Case22 N.A SNV c.2645C>T* p.ARG882HIS possibly-damaging 0.1146 
DNMA3A Case27 AITL SNV c.422T>C p.GLU141GLY benign 0.0326 
DNMA3A Case3 PTCL,NOS SNV c.2391G>C p.ASN797LYS probably-damaging 0.1094 
DNMA3A Case31 AITL SNV c.1910A>T p.LEU637GLN probably-damaging 0.2476 
DNMA3A Case34 AITL SNV c.1969C>T p.VAL657MET probably-damaging 0.0511 
DNMA3A Case35 AITL SNV c.1202A>G p.VAL401ALA benign 0.0359 
DNMA3A Case4 N.A SNV c.1628C>T p.GLY543ASP probably-damaging 0.2929 
DNMA3A Case41 AITL SNV c.1514T>C p.GLU505GLY benign 0.0313 
DNMA3A Case42 AITL SNV c.2458C>A p.GLU820stop unknown 0.1534 
DNMA3A Case42 AITL SNV c.1336C>A p.ALA446SER probably-damaging 0.4571 
DNMA3A Case46 AITL SNV c.2717T>C p.LYS906ARG probably-damaging 0.0323 
DNMA3A Case47 AITL SNV c.2053C>T p.GLY685ARG probably-damaging 0.4308 
DNMA3A Case49 AITL SNV c.1514T>C p.GLU505GLY benign 0.0322 
DNMA3A Case5 PTCL,NOS SNV c.2645C>T* p.ARG882HIS possibly-damaging 0.0336 
DNMA3A Case5 PTCL,NOS SNV c.2207C>T* p.ARG736HIS probably-damaging 0.2206 
DNMA3A Case5 PTCL,NOS SNV c.400T>C p.ASN134ASP probably-damaging 0.0302 
DNMA3A Case53 AITL SNV c.2098G>A p.PRO700SER probably-damaging 0.1947 
DNMA3A Case55 AITL SNV c.2657T>C p.GLN886ARG probably-damaging 0.0385 
DNMA3A Case56 AITL SNV c.332T>C p.LYS111ARG probably-damaging 0.0347 
DNMA3A Case58 AITL SNV c.2330G>T p.PRO777HIS probably-damaging 0.1147 
DNMA3A Case6 AITL SNV c.2690A>G p.VAL897ALA probably-damaging 0.0448 
DNMA3A Case60 AITL SNV c.2645C>T* p.ARG882HIS possibly-damaging 0.1324 
DNMA3A Case62 AITL SNV c.1319C>T p.TRP440stop unknown 0.2049 
DNMA3A Case65 PTCL,NOS SNV c.941C>T p.TRP314stop unknown 0.403 
DNMA3A Case66 AITL SNV c.2644G>A p.ARG882CYS probably-damaging 0.1728 
DNMA3A Case72 ALCL,ALK(-) SNV c.2000T>C p.GLU667GLY probably-damaging 0.0346 
DNMA3A Case75 ALCL,ALK(-) SNV c.2158G>A p.ARG720CYS probably-damaging 0.0645 
DNMA3A Case75 ALCL,ALK(-) SNV c.2067G>C p.SER689ARG possibly-damaging 0.3529 
DNMA3A Case76 ALCL,ALK(-) SNV c.1202A>G p.VAL401ALA benign 0.0308 
DNMA3A Case79 PTCL,NOS SNV c.2653T>C p.ARG885GLY probably-damaging 0.03 
DNMA3A Case82 PTCL,NOS SNV c.1514T>C p.GLU505GLY benign 0.0347 
DNMA3A Case83 PTCL,NOS SNV c.2434T>C p.LYS812GLU benign 0.03 
DNMA3A Case91 PTCL,NOS SNV c.2644G>A p.ARG882CYS probably-damaging 0.2372 
DNMA3A Case91 PTCL,NOS SNV c.2038T>C p.LYS680GLU possibly-damaging 0.032 
DNMA3A Case94 PTCL,NOS SNV c.919G>T p.PRO307THR probably-damaging 0.4029 
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DNMA3A Case95 PTCL,NOS SNV c.2656G>A p.GLN886stop unknown 0.4064 
DNMA3A Case57 AITL indel c.2371delG p.ALA791fs NA 0.2562 
DNMA3A Case30 AITL indel c.792delC p.PRO264fs NA 0.2414 
TET2 Case10 PTCL,NOS SNV c.3893G>A 
p.CYS1298TY
R probably-damaging 0.2897 
TET2 Case10 PTCL,NOS SNV c.4100C>T 
p.PRO1367LE
U probably-damaging 0.1288 
TET2 Case14 AITL SNV c.3743T>G 
p.LEU1248AR
G probably-damaging 0.1773 
TET2 Case19 PTCL,NOS SNV c.5720T>A p.MET1907LYS possibly-damaging 0.4269 
TET2 Case2 AITL SNV c.3646C>T 
p.ARG1216sto
p unknown 0.1805 
TET2 Case22 AITL SNV c.4935T>A p.TYR1645stop unknown 0.0874 
TET2 Case24 AITL SNV c.3320C>G p.SER1107stop unknown 0.0993 
TET2 Case25 AITL SNV c.2191C>T p.GLN731stop unknown 0.2305 
TET2 Case26 AITL SNV c.2428C>T p.GLN810stop unknown 0.2697 
TET2 Case26 AITL SNV c.3646C>T 
p.ARG1216sto
p unknown 0.2094 
TET2 Case28 AITL SNV c.3889G>T p.GLY1297stop unknown 0.0729 
TET2 Case32 AITL SNV c.2368C>T p.GLN790stop unknown 0.1365 
TET2 Case32 AITL SNV c.4960C>T p.GLN1654stop unknown 0.153 
TET2 Case33 AITL SNV c.2899C>T p.GLN967stop unknown 0.1607 
TET2 Case34 AITL SNV c.5353A>T p.LYS1785stop unknown 0.0588 
TET2 Case34 AITL SNV c.5681C>G 
p.PRO1894AR
G probably-damaging 0.0925 
TET2 Case35 AITL SNV c.3119T>G p.LEU1040stop unknown 0.3594 
TET2 Case35 AITL SNV c.3893G>A 
p.CYS1298TY
R probably-damaging 0.1858 
TET2 Case37 AITL SNV c.2797C>T p.GLN933stop unknown 0.1926 
TET2 Case40 PTCL,NOS SNV c.3869C>G p.SER1290stop unknown 0.1716 
TET2 Case42 AITL SNV c.3151C>T p.GLN1051stop unknown 0.0803 
TET2 Case42 AITL SNV c.4475A>T p.GLU1492VAL probably-damaging 0.1574 
TET2 Case43 AITL SNV c.2474C>A p.SER825stop unknown 0.0334 
TET2 Case45 PTCL,NOS SNV c.4870C>T p.GLN1624stop unknown 0.638 
TET2 Case46 AITL SNV c.4082G>T p.GLY1361VAL probably-damaging 0.0818 
TET2 Case46 AITL SNV c.4546C>T 
p.ARG1516sto
p unknown 0.1682 
TET2 Case47 AITL SNV c.5650A>T 
p.THR1884SE
R probably-damaging 0.1781 
TET2 Case47 AITL SNV c.5651C>T p.THR1884ILE probably-damaging 0.177 
TET2 Case5 PTCL,NOS SNV c.5734C>T p.HIS1912TYR probably-damaging 0.238 
TET2 Case50 PTCL,NOS SNV c.3765C>G p.TYR1255stop unknown 0.0844 
TET2 Case51 AITL SNV c.970C>T p.GLN324stop unknown 0.2616 
TET2 Case51 AITL SNV c.3499A>G 
p.ARG1167GL
Y possibly-damaging 0.2689 
TET2 Case57 AITL SNV c.1860C>A p.TYR620stop unknown 0.2152 
TET2 Case58 PTCL,NOS SNV c.3646C>T 
p.ARG1216sto
p unknown 0.2238 
TET2 Case59 AITL SNV c.5647A>C 
p.THR1883PR
O probably-damaging 0.2204 
TET2 Case60 AITL SNV c.2728C>T p.GLN910stop unknown 0.1538 
TET2 Case61 AITL SNV c.5273C>A p.SER1758stop unknown 0.1131 
TET2 Case62 AITL SNV c.1147C>T p.GLN383stop unknown 0.3351 
TET2 Case64 PTCL,NOS SNV c.4960C>T p.GLN1654stop unknown 0.7825 
TET2 Case65 PTCL,NOS SNV c.2746C>T p.GLN916stop unknown 0.254 
TET2 Case66 PTCL,NOS SNV c.1526C>G p.SER509stop unknown 0.0927 
TET2 Case75 ALCL,ALK(-) SNV c.3623A>G 
p.LYS1208AR
G probably-damaging 0.0349 
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TET2 Case75 ALCL,ALK(-) SNV c.4016A>G 
p.LYS1339AR
G possibly-damaging 0.0328 
TET2 Case80 PTCL,NOS SNV c.4126G>A 
p.ASP1376AS
N probably-damaging 0.1602 
TET2 Case82 PTCL,NOS SNV c.4567C>T p.GLN1523stop unknown 0.2597 
TET2 Case85 PTCL,NOS SNV c.2368C>T p.GLN790stop unknown 0.1275 
TET2 Case85 PTCL,NOS SNV c.4312A>T p.LYS1438stop unknown 0.1823 
TET2 Case88 PTCL,NOS SNV c.4076G>A p.ARG1359HIS probably-damaging 0.0862 
TET2 Case90 PTCL,NOS SNV c.3812G>C 
p.CYS1271SE
R probably-damaging 0.1309 
TET2 Case91 PTCL,NOS SNV c.4546C>T 
p.ARG1516sto
p unknown 0.1664 
TET2 Case95 PTCL,NOS SNV c.4354C>T 
p.ARG1452sto
p unknown 0.1303 
TET2 Case74 ALCL,ALK(-) indel c.674delT p.L225fs NA 0.4674 
TET2 Case59 AITL indel c.4404delA p.K1468fs NA 0.4498 
TET2 Case94 PTCL,NOS indel c.2798dupA p.Q933fs NA 0.2793 
TET2 Case38 AITL indel 
c.4899_490
0insG p.C1633fs NA 0.239 
TET2 Case39 AITL indel 
c.2146_214
7del p.S716fs NA 0.2243 
TET2 Case23 ALCL,ALK(-) indel 
c.3308_330
9del p.N1103fs NA 0.217 
TET2 Case65 PTCL,NOS indel c.2295delC p.S765fs NA 0.2084 
TET2 Case52 AITL indel c.2045delA p.H682fs NA 0.2035 
TET2 Case76 ALCL,ALK(-) indel c.4353delG p.R1451fs NA 0.1945 
TET2 Case38 AITL indel c.2304delT p.D768fs NA 0.1902 
TET2 Case5 PTCL,NOS indel c.5147delA p.H1716fs NA 0.1781 
TET2 Case48 AITL indel c.3342delT p.T1114fs NA 0.1681 
TET2 Case53 AITL indel c.2213delT p.L738fs NA 0.1525 
TET2 Case46 AITL indel c.1169delA p.D390fs NA 0.1385 
TET2 Case91 PTCL,NOS indel c.1836delT p.P612fs NA 0.1252 
TET2 Case47 AITL indel c.1142delT p.F381fs NA 0.1168 
TET2 Case41 AITL indel c.4629delA p.R1543fs NA 0.1166 
TET2 Case29 AITL indel c.982delG p.V328fs NA 0.1157 
TET2 Case37 AITL indel 
c.1059_106
0del p.C353fs NA 0.1135 
TET2 Case28 AITL indel 
c.3312_331
5del p.F1104fs NA 0.1021 
TET2 Case90 PTCL,NOS indel 
c.5059_506
0del p.Q1687fs NA 0.098 
TET2 Case80 PTCL,NOS indel c.1236delT p.L412fs NA 0.0959 
TET2 Case95 PTCL,NOS indel c.3764dupA 
p.Y1255_G125
6delinsX NA 0.088 
TET2 Case31 AITL indel c.1123delG p.E375fs NA 0.0856 
TET2 Case6 AITL indel c.3965delT p.L1322fs NA 0.0693 
TET2 Case68 AITL indel c.649delT p.S217fs NA 0.0638 
TET2 Case4 AITL indel c.2304delT p.D768fs NA 0.0389 
TET2 Case50 PTCL,NOS indel c.4689delT p.S1563fs NA 0.0379 
*	  denote	  the	  SNV	  showed	  in	  dbSNP	  database	  but	  not	  50%	  in	  our	  sample;	  SNV:	  single-­‐nucleotide	  
variant;	  indel:	  insertion/deletion;	  fs:frame	  shift;	  NA:	  Not	  appliable	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Table 3.2 GSEA pathway analysis showing selected pathways (and their P values) 
different between IDH2/TET2 double-mutant and TET2 single-mutant AITL. 
Pathw
ay 
Categ
ory  
Enriched 
Group Pathway Name  
Pathway 
Source  NES  
NOM  
(p-
value ) 
FDR  
(q-value) 
T cell 
differe
nciatio
n  
Double 
Mutant EARLY_T_LYMPHOCYTE_UP  LEE  1.980 0.000 0.001 
 
Double 
Mutant FOXP3_TARGETS_CLUSTER_P6  GAVIN  1.961 0.000 0.002 
 
Double 
Mutant FOXO3_TARGETS_DN  DELPUECH  1.603 0.014 0.076 
 
Double 
Mutant EZH2_TARGETS  KAMMINGA  1.939 0.000 0.003 
 
Double 
Mutant HYPOXIA_DN  MANALO  1.923 0.000 0.003 
 
Double 
Mutant 
TCA_CYCLE_AND_RESPIRATORY_ELEC
TRON_TRANSPORT  REACTOME  1.744 0.000 0.024 
 
Double 
Mutant MITOCHONDRIA_GENE_MODULE  WONG  1.581 0.003 0.088 
 
Double 
Mutant MYC_TARGETS_UP  COLLER  1.646 0.013 0.055 
Cytoki
nes 
and 
Interle
ukins  
Double 
Mutant TGFB1_SIGNALING  KARAKAS  1.513 0.054 0.141 
H3K27
me3  
Double 
Mutant MEF_ICP_WITH_H3K27ME3  MIKKELSEN  1.571 0.000 0.095 
 
Double 
Mutant PROSTATE_CANCER_WITH_H3K27ME3 KONDO  1.559 0.000 0.104 
 
Double 
Mutant IPS_WITH_HCP_H3K27ME3  MIKKELSEN  1.533 0.003 0.126 
 
Double 
Mutant MEF_HCP_WITH_H3K27ME3  MIKKELSEN  1.504 0.000 0.146 
Apopt
osis  
Double 
Mutant APOPTOSIS_BY_CDKN1A_VIA_TP53  WU  1.875 0.000 0.005 
 
Double 
Mutant 
CELL_CYCLE_TARGETS_OF_TP53_AND_
TP73_DN  SCIAN  1.985 0.000 0.001 
 
Double 
Mutant RETINOBLASTOMA_PATHWAY_UP  VERNELL  1.799 0.000 0.014 
Cell 
Cycle  
Double 
Mutant CELL_CYCLE_LITERATURE  WHITFIELD  2.261 0.000 0.000 
 
Double 
Mutant G1_S_TRANSITION  REACTOME  1.874 0.000 0.005 
 
Double 
Mutant M_G1_TRANSITION  REACTOME  1.863 0.000 0.006 
 
Double 
Mutant MITOTIC_G1_G1_S_PHASES  REACTOME  1.849 0.000 0.008 
 
Double 
Mutant CELL_CYCLE_RB1_TARGETS  EGUCHI  1.922 0.000 0.003 
IFN 
signali
ng  
Single 
Mutant 
INTERFERON_INDUCED_ANTIVIRAL_MO
DULE  BOSCO  1.880 0.012 0.513 
JAK-
STAT  
Single 
Mutant STAT3_TARGETS_DN  DAUER  1.850 0.012 0.445 
 
Single 
Mutant STAT5A_TARGETS_DN  WIERENGA  1.730 0.000 0.447 
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Single 
Mutant NOTCH1_TARGETS_DN  VILIMAS  1.780 0.000 0.459 
 
Single 
Mutant IL1PATHWAY  PID  1.730 0.021 0.435 
  
Single 
Mutant RESPONSE_TO_IFNA1_UP  RADAEVA  1.720 0.047 0.406 
NES: normalized enrichment score 
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Table 3.3 Pyrosequencing primer sequences. 
Gene 
Sense Primer  
(5’ to 3’) 
Anti-sense Primer  
(5’ to 3’) 
Sequencing Primer  
(5’ to 3’) 
PCR 
(bp) 
Anneal. 
°C 
IDH2 
TAGTCCCTGGCTGG 
ACCAAGCCCATCAC 
AGTGCCGGCCCGGT 
CTGCCACAAAGTCT 
AGCCCATCACCATTG 179* 63 
    95**  
 
*Genomic DNA PCR product is 179 bases. 
 ** cDNA PCR product is 95 bases. 
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Summary 
Genetic and epigenetic alterations collaboratively contribute to the onset and progress of 
cancers. The epigenetic changes induced by IDH2, TET2, and DNMT3A mutations and 
their roles in AITL pathogenesis are still largely unknown. As discussed in Chapter 3, 
IDH2R172 mutations define a distinct group of AITL patients. Here, we investigated the 
biochemical and functional consequences of IDH2R172 mutations in T cells and AITL. 
Ectopic expression of IDH2R172K in the Jurkat cell line and CD4+ T cells led to markedly 
increased levels of 2-hydroxyglutarate, histone-3 lysine methylation, and 5-
methylcytosine and a decrease of 5-hydroxymethylcytosine. Correspondingly, clinical 
samples with IDH2 mutations displayed a prominent increase in H3K27me3 and DNA 
hypermethylation of gene promoters. Integrative analysis of gene expression and 
promoter methylation revealed recurrently hypermethylated genes involved in TCR 
signaling and T cell differentiation that likely contribute to lymphomagenesis in AITL. 
Current findings indicate a novel target for the treatment of AITL patients. 
Introduction  
Epigenetic alterations are defined as heritable changes of gene expression 
without alterations of DNA sequences. Epigenetic changes, including DNA methylation, 
histone modifications, and microRNAs (miRNAs), are linked to gene regulation and 
developmental processes. DNA methylation is the most stable epigenetic modification 
and involves addition of a methyl group to the cytosine in CG dinucleotides. A large 
fraction of CpG are found in CpG islands (CGIs), which are dense regions of CG 
dinucleotides. A large fraction of gene promoters lie within CGIs, and most CGIs are not 
normally methylated. 5-methylcytosine (5mC) is a critical epigenetic mark for a variety of 
biological and pathological processes. 5-hydroxymethylcytosine (5hmC) is created by 
oxidation from 5mC by the ten-eleven translocation (TET) family of DNA hydroxylase. 
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Loss of 5-hmC is considered as an epigenetic hallmark of several malignancies, related 
to downregulation TET2 and IDH2 activity (Lian et al., 2012). A histone modification is a 
covalent post-transcriptional modification of histone tails. It includes methylation, 
acetylation, phosphorylation, sumoylation, and ubiquitylation. Histone 3 (H3) is the most 
modified histone, and its modifications are commonly used to determine whether the 
elements are in active or repressed state. For instance, tri-methylation of K4 and K36 on 
H3 (H3K4me3 and H3K36me3) are active marks. Tri-methylation of K27 and K9 on H3 
(H3K27me3 and H3K9me3) are repressed marks. Histone acetylation is commonly 
associated with an open chromatin structure and often target promoter regions. For 
instance, acetylation of K27 on H3 (H3K27ac) is associated with promoter and enhancer 
regions of active genes. 
It has become clear that both genetics and epigenetic changes contribute to 
cancer onsets and progression. The aberrant DNA and histone methylation identified in 
various malignancies suggests an important role for these epigenetic changes in 
tumorigenesis, although the profiles vary among tumors, indicating a possible 
dependency on cellular context. Mutations of epigenetic regulators (IDH2R172, TET2, and 
DNMT3A) are common in AITL, emphasizing the importance of aberrant epigenetic 
alterations in lymphomagenesis. Given the presence of TET2 and DNMT3A mutations in 
other subtypes of PTCL, but not IDH2R172 mutations, it is highly likely that IDH2R172 
mutations play a unique role in the pathogenesis of AITL. Indeed, unsupervised 
hierarchical clustering identified a distinct GEP associated with IDH2R172 mutations in 
AITL. The changes in GEP in IDH2R172 mutant cases likely resulted in part from promoter 
hypermethylation, but also from disruption of histone lysine demethylation. 
Oncogenic IDH2 and TET2 mutations have been reported in acute myeloid 
leukemia (Delhommeau et al., 2009; Marcucci et al.; Saint-Martin et al., 2009), 
myelodysplastic syndromes (Kosmider et al., 2009; Kosmider et al.), glioblastomas (Kim 
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et al.; Yan et al., 2009) and recently in peripheral T-cell lymphomas . IDH2R172 mutations, 
similar to the IDH1 counterparts, alter the enzymatic activity, leading to the generation of 
the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG) instead of α-ketoglutarate (α-KG) 
(Koivunen et al., 2012; Losman et al., 2013). (R)-2HG is an oncometabolite (Koivunen et 
al., 2012; Losman et al., 2013) that competitively inhibits α-KG-dependent dioxygenases, 
which include the TET family of methylcytosine hydroxylases and histone demethylases 
(Xu et al.). Therefore, IDH2 neomorphic mutations and TET2 loss of function mutations 
are expected to induce DNA hypermethylation of the affected cells.  
Mitochondrial IDH2 protein and cytosolic IDH1 protein are homologues. 
Surprisingly, unlike other malignancies (Mardis et al., 2009; Yan et al., 2009), AITL 
harbors mutations only at IDH2R172, but not at IDH2R140 or in IDH1. In the tricarboxylic 
acid cycle, IDH3 catalyzes the oxidative decarboxylation of isocitrate to α-KG. Under 
anabolic conditions, IDH2 primarily catalyzes the reverse reaction, reductive 
carboxylation of α-KG to isocitrate. The IDH2R172 mutation confers a neomorphic 
activity—namely, conversion of α-KG to the R-2-HG (Guilhamon et al., 2013), which, in 
normal cells, is maintained at low concentrations by 2-HG dehydrogenase. R-2-HG acts 
as a competitive antagonist of the α-KG-dependent dioxygenases (Xu et al., 2011), 
which notably include the TET family of 5-methylcytosine hydroxylases and jumonji-C 
domain-containing histone demethylases (JHDMs) (Chowdhury et al., 2011; Loenarz 
and Schofield, 2008; Xu et al., 2011).	  Thus, mutant IDH2R172 is predicted to impair DNA 
and histone demethylation and leads to abnormal regulation of gene transcription, which 
may promote lymphomagenesis. 
The epigenetic alterations induced by IDH2, TET2, and DNMT3A mutations and 
their roles in AITL pathogenesis are still largely unknown. As discussed in Chapter 3, 
IDH2R172 mutations define a distinct group of AITL patients. The biochemical and 
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functional consequences of IDH2R172 mutations in T cells have not yet been elucidated. 
Here, we analyzed the biochemical changes associated with IDH2R172 mutations and 
investigated alterations in DNA methylation and histone modification to improve our 
understanding of their roles in the pathogenesis of AITL. 
Results  
IDH2R172 mutations result in DNA hypermethylation in T cells 
To investigate the effect of IDH2R172 mutations on the T-cell methylome, we 
transduced Jurkat cells and primary CD4+ T cells with vectors expressing IDH2R172K or 
wild-type IDH2. As anticipated, ectopic expression of mutant IDH2 resulted in increased 
intracellular 2-HG in Jurkat cells (Figure 4.1 A). Remarkably, a global increase in 5mC 
and a global decrease in 5hmC were observed in the DNA of Jurkat cells expressing the 
IDH2R172K mutant compared with cells expressing wild-type IDH2 or empty vector (Figure 
4.1A and B), indicating that IDH2R172K mutation leads to epigenetic changes in DNA 
through 2-HG. Similar results for 2-HG, 5mC, and 5hmC were observed in primary CD4+ 
T cells (Figure 4.1C-E).  
IDH2R172 mutations are associated with DNA hypermethylation in AITL  
To determine the genome-wide methylation profiles of AITL cases with IDH2R172 
mutations and compare them with the profiles of wild-type cases, we first performed 
methyl-sensitive cut counting (MSCC) to identify the relative changes in global CpG 
methylation in genomic DNA from 18 AITL cases and 5 normal tonsils. Normalized 
methylation counts from all the genes were compared among normal tonsils (n=5), AITL 
cases with IDH2R172 mutations (n=8) and AITL cases without IDH2R172 or TET2 mutations 
(n=5) in different regions of genes, including distal promoter, proximal promoter, gene 
body and 3’ UTR. Only in the proximal promoter region (-1.5 kb to +0.5 kb relative to the 
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transcriptional start site) was there a significant difference between the normal tonsil 
group and the IDH2R172 mutant group. Lower counts in the IDH2R172 mutant group imply 
that many proximal promoters are hypermethylated. To be more specific, we analyzed 
more detailed regions in the -1.5 kb to +0.5 kb promoter regions. The data revealed that 
the hypermethylation was more focused near the transcriptional start site. Together, the 
data demonstrated that aberrant hypermethylated promoters are associated with 
IDH2R172 mutations in AITL (Figure 4.2). The endonuclease HpaII used in MSCC is 
methyl-sensitive, so only the unmethylated cytosines in the CCGG site can be cut. In 
some of our AITL samples, the tumor content is low. The count differences might be 
obscured by a large fraction of stromal cells which hypothetically have more 
unmethylated cytosine. In this case, the reduced representation bisulfate sequencing 
(RRBS) approach can be utilized since the methyl-insensitive restriction enzyme MspI 
would be used first. RRBS also provides quantitative, single-base resolution methylation 
data for a portion of the human genome that is enriched for CpG islands. 
We conducted RRBS to investigate the genome-wide alterations in DNA 
methylation in 18 AITL cases with relatively high tumor content, and compared them with 
T-cell samples isolated from peripheral blood of four donors. Most of AITL cases with 
high tumor content harbor TET2 mutations (17/18) and 10 out of 18 cases harbor 
IDH2R172 mutations. Since AITL tumors have a considerable number and variety of non-
malignant cells, we included three tonsils to serve as additional controls to filter out 
differences resulting from cell type-specific methylation of non-malignant cells.  
Studies in several cancers have shown that gain-of-function mutation of IDH2 is 
associated with a DNA hypermethylation phenotype (Guilhamon et al., 2013), possibly 
through inhibition of TET2. Compared to normal tissues, IDH2 mutant AITL showed 
global alterations of the DNA methylation landscape including hypermethylation of 
regulatory regions, such as promoters and CpG islands (CGIs) (Figure 4.3 F) that are 
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known to be correlated with downregulation of gene transcription while gene body and 
intergenic regions are hypomethylated (Harris et al., 1994). CpG island shores (CGSs) 
are ± 2 kb regions flanking CGI, and CGI and CGS are normally unmethylated for most 
genes. We classified promoters into CGI-associated promoters, CGS-associated 
promoters and non-CGI/CGS-associated promoters. We observed global 
hypermethylation of CGI-associated promoters and global hypomethylation of non-
CGI/CGS-associated promoters in both IDH2 mutant and wild-type AITL (Figure 4.3 G). 
We observed that IDH2 wild-type AITL had hypermethylation of many genes that are 
normally not expressed in CD4+ T cells. However, among genes normally expressed in 
CD4+ T-cells, a significantly higher number were hypermethylated in the IDH2 mutant 
group (Figure 4.3 H), indicating a more significant functional effect of IDH2R172 mutations 
in AITL. In addition, we sought to define the methylation targets of mutant IDH2 by 
comparing the methylation profiles of IDH2 wild-type and IDH2R172 mutant AITL using the 
following criteria: (a) selected genes are normally expressed in primary CD4+ T cells; (b) 
gene expression is significantly lower in the IDH2R172 mutant group than the IDH2 wild-
type group (P < 0.05); (c) promoter methylation in the IDH2R172 mutant group is 
significantly higher than that in the IDH2 wild-type group (P < 0.05); and (d) promoter 
methylation and gene expression correlate in the samples (R < -0.3). Table 4.1 shows 
46 aberrantly hypermethylated genes with repression of transcription, including negative 
regulators of TGF-β signaling (SMAD7 and SMURF2) and CD7 (Figure 4.4). CD7 is 
reported to be a negative prognostic marker in myeloid malignancies (Kagami et al., 
2001; Lee et al., 2012). Lack or diminished expression of CD7 on malignant T cells has 
often been observed in T-cell lymphoma, including AITL, but the underlying mechanisms 
are not clear. However, we found a strong correlation between down-regulation of CD7 
and hypermethylation of its promoter (Figure 4.4). Importantly, CD7 is essential for 
galectin-1-mediated T-cell death (Roberts et al., 2015). Lack of CD7 on Sézary cells is 
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thought to contribute to resistance to galectin-1-mediated apoptosis (Chapuy et al., 2013; 
Farrell and Sears, 2014; Gregory and Hann, 2000).   
Genes involved in TCR signaling and T cell differentiation are recurrently 
hypermethylated in AITL  
Of the 3557 genes (of 17,179 evaluable genes) with differentially methylated 
promoters in AITL cases compared to the normal samples (P < 0.05), 2728 were 
hypermethylated and 829 were hypomethylated. To identify the differentially methylated 
genes most likely to be aberrantly up- or downregulated due to abnormal DNA 
methylation, we utilized additional criteria: (a) selected genes must be normally 
expressed in primary CD4+ T cells, and (b) there must be strong correlation between 
promoter methylation and gene expression among the samples (R < -0.4).  To identify 
genes whose expression is likely downregulated by promoter methylation, we selected 
differentially methylated promoters in AITL cases compared with normal tissues. A total 
of 46 hypermethylated genes and nine hypomethylated genes in AITL were identified 
having strong correlation (R < -0.4) with transcriptional changes (Figure 4.5). The 
epigenetically downregulated genes included negative regulators of TCR signaling 
(PTPN7, SIT1, and DGKA), positive regulators of Th1 activity (MATK and PHF11), and 
other cell surface marker genes (CD7 and IL10RA) (Figure 4.4). PTPN7, a member of 
the protein tyrosine phosphatase (PTP) family, is preferentially expressed in various 
hematopoietic cells and is involved in inhibiting TCR-mediated signal transduction (Chen 
et al., 2016; Zhao et al., 2016). SHP2-interacting transmembrane adaptor protein (SIT) is 
normally expressed on lymphocytes, and loss of SIT can enhance TCR-mediated Akt 
activation and T-cell homeostasis (Xie et al., 2016). Diacylglycerol kinase α, encoded by 
DGKA, functions as a negative regulator of TCR signaling by decreasing diacylglycerol 
levels and inducing anergy (Wu et al., 2016). Matk/CHK, encoded by MATK, is an 
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important modulator of immune cell signaling.  Knockout of this kinase reduced IFN-γ 
secretion by T-cells upon immune challenge (Ji et al., 2016). Expression of plant 
homeodomain finger protein 11 (PHF11) can positively regulate Th1 cytokines (Yang et 
al., 2016a). In addition, downregulation of IL10RA may be important as IL-10 signaling 
has negative effects on Tfh cells (Yang et al., 2016b) including their proliferation. These 
results suggest T-cell differentiation and homeostasis are dysregulated epigenetically in 
AITL.  
Promoter hypermethylation of tumor suppressor genes (TSGs) is a common 
mechanism for downregulation in malignancies. Phospholipase C δ1 (PLCD1) is a TSG 
which is able to induce G2/M arrest. This gene is reported to be methylated in other 
types of cancers, including breast cancer and chronic myelogenous leukemia (Spencer 
and Groudine, 1991; Welcker et al., 2004). Zinc-finger and BTB domain containing 4 
(ZBTB4) appears to act as a TSG in breast cancer by repressing EZH2 and the Sp1 
family (Flavahan et al., 2016). Downregulation by promoter hypermethylation of ZBTB4 
may be related to the EZH2 activation observed in AITL (data not shown). 
Dihydropyrimidinase-related protein 4 (DPYSL4) is an apoptosis-inducible factor 
regulated by p53 (Tong et al., 2016) and is reported to be hypermethylated in 
hepatocellular carcinoma (Choi et al., 2011).  
IDH2R172 mutations are associated with enhanced H3K27me3 in AITL and T cells 
One of the most striking findings from GSEA analysis of the genes differentially 
expressed among wild-type, TET2 single-mutant, and IDH2/TET2 double-mutant groups 
was the enrichment of genes associated with the repressive mark histone 3 
trimethyllysine-27 (H3K27me3) (Figure 4.6A). We analyzed genes with both H3K4me3 
and H3K27me3 in human embryonic stem cells (hESCs) (“poised” genes) as these 
genes are particularly prone to repression by H3K27me3. Indeed, hESC-poised genes 
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expressed in CD4+ T cells are downregulated in AITL with IDH2R172 mutations (Figure 
4.6B). Initially H3K27me3-repressed genes are prone to cancer-specific promoter DNA 
hypermethylation, definitively silencing them (Xu et al., 2016). Thus, we compared DNA 
methylation between hESC-poised genes and non-hESC poised genes and found that 
poised genes are significantly more likely to be hypermethylated than non-poised genes 
(Figure 4.6 C).  
To determine whether the mutant IDH2R172 can alter histone lysine methylation in 
vitro, we ectopically expressed mutant IDH2R172K, wild-type IDH2, and empty vector in 
Jurkat cells (Figure 4.7A). H3K27me3, H3K9me3, and H3K4me3 were significantly 
increased in Jurkat cells expressing IDH2R172K (Figure 4.7B). Immunohistochemical 
staining revealed significantly enhanced H3K27me3 in the IDH2R172 mutant AITL cases 
group (n = 3) (average 42.2% positive cells) compared to cases in the IDH2 wild-type 
group (n = 3) (average 16.2% positive cells) (Figure 4.7C). Strongly positive areas 
averaged only 2.9% in the IDH2 wild-type cases, but constituted 18.8% in the IDH2R172 
mutant cases (Figure 4.7D). Overall, these data demonstrate increased H3K27me3 both 
in vitro and in tumor samples in agreement with our GEP findings and strongly suggest 
that IDH2R172K mutations can dysregulate the post-translational modification of histones 
in T cells. 
Discussion 
Little is known about the pathogenesis of AITL. Current therapeutic interventions 
are not sufficient to improve the outcome of patients suffering from this disease. Further 
studies may provide novel targets for efficient treatments and new biomarkers for more 
accurate diagnosis of this disease. 
 Unlike in AML, IDH2 and TET2 mutations are not mutually exclusive in AITL. 
Despite the significant differences between IDH2/TET2 double-mutant AITL and normal 
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tissues, and between TET2 single-mutant AITL and normal tissues, there is only a 
moderate difference in genome-wide methylation between IDH2/TET2 double-mutant 
and TET2 single-mutant AITL, which seems insufficient to explain the much greater 
differences on GEP. However, GEP includes secondary changes from genetic and 
epigenetic alterations. The significant changes in gene expression in the IDH2R172 
mutant group may also represent consequences of histone modification.  
Mutant IDH2 inhibits various histone demethylases. Nearly all histone 
demethylation is brought about by the Jumonji family of histone demethylases, with 27 
distinct enzymes in humans. H3K4, H3K9, H3K27, and H3K79 methylation has been 
shown to be elevated in glioma cells expressing mutant IDH1/2, both in vitro and in vivo 
(Lu et al., 2012). Consistent with this finding, we observed similar alterations in vitro and 
significantly elevated levels of H3K27me3 in AITL cases with IDH2R172 mutation, 
suggesting that 2-HG produced by IDH2 mutants indeed interferes with histone 
demethylases. In ESCs, bivalent chromatin modification is thought to silence genes 
controlling cell lineage through the repressive histone mark H3K27me3, while rending 
them “poised” for subsequent activation during differentiation through H3K4me3. Histone 
lysine demethylases (KDM) 6A/B are responsible for demethylating H3K27me3. 
Inactivating mutations of KDM6A have frequently been identified in hematopoietic 
malignancies and solid tumors (Choi et al., 2011; Lin et al., 2016b). Genes that are 
poised in ESCs are especially likely to be persistently “turned off” by H3K27me3 due to 
inhibition of KDM6A/B by mutant IDH2. In the context of AITL, our results suggest that 
IDH2R172 mutation further promotes lymphomagenesis by altering gene expression 
through histone lysine methylation. This hypothesis is supported by the observation that 
hESC-poised genes were significantly downregulated in the IDH2R172 mutant group. 
Aberrant repression by H3K27me3 may be induced, albeit less readily, in other genes 
that are downregulated in IDH2R172 mutant AITL. In both IDH2R172 mutant and wild-type 
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cases, genes with little or no expression in T-cells are especially likely to undergo 
promoter DNA hypermethylation. Thus, some of the genes aberrantly repressed by 
H3K27me3 may later become hypermethylated in their promoters, locking in their 
transcriptional silencing (Figure 4.8). Thus, loss-of-function of TET2 and histone 
demethylases may cooperate in epigenetic dysregulation.  
(R)-2-HG generated from mutant IDH is sufficient to promote leukemogenesis 
(Losman et al., 2013). Aside from DNA methylation and histone modificatioans, elevated 
(R)-2HG alters many other cellular processes, including collagen maturation and hypoxia 
HIF-stabilization, through competitively inhibit many other α-KG-dependent 
dioxygenases.  It has been report that the (S)-enantiomer is more potent than (R)-
enantiomer in terms of inhibiting several dioxygenases. EglN (Egg-laying defective Nine) 
prolyl hydroxylases catalyze hydroxylation of prolyl-redisues in HIF, a post-translational 
modification that signals for proteosomal degradation. Several studies reported that (R)-
2HG, but not (S)-2HG, promotes EglN activities (Xu et al., 2011). A later paper provides 
evidence that the stimulatory effect is through non-enzymatic production of α-KG from 2-
HG (Tarhonskaya et al., 2014). It does seem that (R)-2-HG is a weaker inhibitor of the 
prolyl hydroxylases than it is of many of the other dioxygenases. Thus, the role of IDH 
mutations in regulating HIF needs to be clarified. 
Both IDH2R172 and TET2 mutations can lead to promoter hypermethylation, giving 
a strong rationale for considering the use of hypomethylating agents and HDAC 
inhibitors in AITL treatment. TET2-mutated myelodysplastic syndrome patients have 
been shown to response to hypomethylating agents (Hnisz et al., 2013). Moreover, a 
case report using 5-azacytidine to treat a patient with chronic myelomonocytic leukemia 
(CMML), who also had TET2-mutant AITL, led to a complete remission of both the AITL 
and CMML (Loven et al., 2013). VEGF-A has been showed to be over-expressed in 
malignant cells and endothelial cells from AITL and associated with an adverse 
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prognosis (Zhao et al., 2004), suggesting that it is another potential therapeutic target. A 
small molecule inhibitor targeting mutant IDH2, AG-221, has also shown promising 
results in treating IDH2-mutant AML in animal models and in clinical trials (Huang et al., 
2016; Jia et al., 2016), suggesting that inhibition of mutant IDH2 could be a useful 
therapeutic strategy that specifically targets an oncogenic mutation in AITL. However, 
since most IDH2-mutant cases also have TET2 mutations, it is possible that combination 
with a DNA hypomethylating agent or anti-angiogenic drugs could improve efficacy. 
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Figures 
Figure 4.1 IDH2R172 mutations are associated with DNA hypermethylation in AITL 
and T cells. 
(A and B) Simultaneous detection of 5mC and 5hmC in transduced Jurkat cells by the 
LC-MS/MS method. (C and D) Simultaneous detection of 5mC and 5hmC in transduced 
human CD4+ T cells by the LC-MS/MS method. (E) LC-MS/MS showing alteration of 
intracellular 2-HG in corresponding groups (n = 4 each).  
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Figure 4.2 Comparation of methylation count among tonsil and AITL cases.  
(A) Regions from -8.0 kb to 3’UTR. (B) MSCC counts within different functional regions 
of genes among tonsils, IDH2 wild-type AITL, and IDH2 mutant AITL. (C) Regions from -
1.5 kb to +0.5 kb, divided into 500 bp intervals. 
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Figure 4.3 IDH2R172 mutations are associated with DNA hypermethylation in AITL 
and T cells. 
(A) RRBS showing alterations of methylation level among normal tissues (n = 7, three 
tonsils and four CD4+ T-cell samples), IDH2 wild-type AITL (n = 8), and IDH2R172 mutant 
AITL (n = 10) in different genomic regions. Promoters are ± 1kb regions relative to 
transcription start site (TSS). Gene bodies are regions of transcribed sequences 
excluding promoter regions. Intergenic regions are the sequences other than promoters 
and gene bodies. (B) RRBS showing alterations of methylation level in CpG island 
(CGI), CpG island shore (CGS) and non-CGI-CGS regions. (C) Number of 
hypermethylated genes in IDH2 wild-type AITL (n = 8), and IDH2R172 mutant AITL (n = 
10) compared with normal tissues. Red indicates genes only hypermethylated in 
IDH2R172-mutant AITL. Green indicates genes only hypermethylated in IDH2 wild-type 
AITL. Blue indicates genes hypermethylated in both IDH2R172 mutant and IDH2 wild-type 
AITL. Genes with expression data were divided into deciles based on the mean gene 
expression level of five normal CD4+ T cell samples (10 = highest). Data are shown as 
mean ± SEM. P value was calculated using the two-tailed Student’s t test. * indicates P < 
0.05, ** indicates P <0.01, *** indicates P < 0.001.  
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Figure 4.4 CD7 is hypermethylated in IDH2R172 mutant AITL and correlates strongly 
with gene downregulation.  
(A) CD7 promoter was significantly hypermethylated in AITL compared to primary CD4+ 
T cells. Each dot shows the fraction of methylation at an individual CpG site near the 
transcriptional start site. Dark indicates higher fraction of methylation. (B) CD7 
expression are decreased in AITL. mRNA levels are based on probe 214049_x_at using 
Affimatrix array. (C) Expression of CD7 was correlated with promoter methyaltion in AITL.  
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Supplemental Figure 8. CD7 is hypermethylated in IDH2R172 mutant AITL and correlates strongly with gene downregulation.  
(A) CD7 promoter was significantly hypermethylated in AITL compared to primary CD4+ T cells. Each dot shows the fraction of methylation  
at an individual CpG site near the transcriptional start site. Dark indicates higher fraction of methylation. (B) CD7 expression are decreased  
in AITL. mRNA levels are based on probe 214049_x_at using Affimatrix array. (C) Expression of CD7 was correlated with promoter  
methyaltion in AITL.  
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Figure 4.5 RRBS methylation analysis (left) and gene expression analysis (right) of 
46 hypermethylated and 9 hypomethylated genes between 18 AITL and 7 normal 
samples. 
Gene selection criteria include: (a) Promoters of the selected genes must be significantly 
hyper- or hypo-methylated compared with normal tissue (three tonsils and four CD4+ T-
cell samples) (P ≤ 0.05); (b) selected genes must be normally expressed in primary 
CD4+ T cells; and (c) there must be strong correlation between promoter methylation 
and gene expression among the samples (R < -0.4). Except for one case (indicated with 
*), all cases with RRBS data have corresponding gene expression data. Mutational 
statuses of IDH2R172, TET2, and DNMT3A are listed at the top.  
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Figure 4.6 Poised genes tend to be downregulated and hypermethylated in 
IDH2R172 mutant AITL. 
(A) GSEA analysis of genes differentially expression between TET2-single mutant and 
IDH2/TET2-double mutant groups showed the enrichment of H3K27me3-associated 
genes. (B) Poised genes expressed in CD4+ T cells are downregulated in AITL with 
IDH2R172 mutations. (C) Compared the DNA methylation patterns between poised genes 
and non-poised genes in AITL. The poised genes are significantly more likely to be 
hypermethylated than non-poised genes (P = 1.3 X 10-17, Fisher’s exact test).   
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Figure 4.7 IDH2R172 mutant alters histone lysine trimethyaltion in the Jurkat T cells 
and AITL. 
(A) Western blots showing ectopic expression of wild-type IDH2 and IDH2R172 in whole 
cell lysates of transduced Jurkat cells. LC-MS/MS showing alteration of intracellular 2-
HG in corresponding groups (n = 4 each, data are shown as mean ± SEM, *** P < 0.001 
by two-tailed Student’s t test). (B) Western blots showing changes in trimethylation of 
various histone lysine residues in transduced Jurkat cells. Histone proteins were 
extracted and assessed for expression levels of histone lysine methylation. Total H3 was 
utilized as loading control.  Blots shown are representative of at least three replicates. 
(C) Representative immunohistochemistry of AITL tissue microarrays with antibody 
against H3K27me3 (n = 3 in each group). Original magnification, x40. (D) Image 
quantification using Image Scope (details in Methods section). Error bar indicates SEM 
of three independent samples in each group. 
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Figure 4.8 Proposed model of the role of IDH2R172 and TET2 mutations in AITL. 
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Tables 
Table 4.1 Top 46 genes most significantly hypermethylated in promoter regions 
and dowregulated in IDH2 mutant AITL.
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Table 4.2 Primary antibodies used for western blots. 
 
Antibody Supplier Dilution 
anti-IDH2 ab55271, Abcam 1:1000 
anti-FLAG tag MA1-91878, Thermo Scientific 1:1000 
anti-α-Tubulin T6074,Sigma 1:5000 
anti-H3 4499, Cell Signaling Technology 1:1000 
anti-H3K4me3 ab8580, Abcam 1:1000 
anti-H3K9me3   ab8898, Abcam 1:1000 
anti-H3K27me3 07-449-Millipore 1:4000 
anti-H3K36me3 ab9050, Abcam 1:1000 
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Chapter 5 Major conclusions and future directions 
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Major conclusions 
This dissertation describes the exciting discovery of mutations affecting 
epigenetic regulators (IDH2, TET2, and DNMT3A) and their role in peripheral T-cell 
lymphomas. The pathogenesis of peripheral T cell lymphoma is not clear. The 
pathological diagnosis of this group of diseases remains challenging. We described a 
method in Chapter 2 for identification of the clonal T cell population and investigating the 
features of TCR repertoire in PTCL to facilitate the diagnosis and showed that RNA-seq 
is a useful tool for detecting clonality in PTCL. 
In Chapter 3, we described the discovery of recurrent mutations affecting 
epigenetic regulators (IDH2, TET2, and DNMT3A) in PTCLs. Mutations affecting 
epigenetic regulators are more frequent in AITL than other subtypes of PTCL. IDH2R172 
mutations define an AITL subgroup with a distinct gene expression signature. IDH2R172 
mutations also appear to be a unique marker of AITL and will facilitate the molecular 
diagnosis of the disease and differential diagnosis with other subtypes of PTCLs. 
IDH2 was the first gene found to be frequently mutated in AITL, and it is also 
mutated in other malignancies. There is a rational mechanistic basis for its presumed 
role in the pathogenesis of AITL. In Chapter 4, we performed a functional study of 
IDH2R172 in AITL. This study provided critical information on the epigenetic alterations in 
AITL associated with IDH2R172 mutations. The combination of DNA sequencing, gene 
expression profiling, and epigenetic analysis identified genes whose abnormal 
methylation likely contributes to transformation of AITL. Our in vitro study showed that 
IDH2R172 mutations are associated with DNA hypermethylation and enhanced 
H3K27me3 in AITL and T cells. By identifying pathways and networks affected, we 
integrated the effects of the epigenetic lesions and identified potential targets for new 
therapies that may improve the outcome of AITL patients.  
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Future directions 
Identification of H3K27me3 and H3K27ac profiles in AITL using ChIP-seq 
IDH2 mutations affect not only DNA methylation, but also histone modifications. 
Data in Chapter 4 revealed an association between a global increase of H3K27me3 and 
IDH2R172 mutations. To study which oncogenic genes are altered through modulating 
H2K27me3 and differentially expressed in IDH2R172 mutant cases, we will perform ChIP-
seq of H3K27me3 in cases with or without IDH2 mutations and combine the results with 
corresponding gene expression profiling analysis. Fresh frozen tissues are limited for 
studying peripheral T cell lymphomas.  Formalin-fixed, paraffin-embedded (FFPE) 
samples are the standard method for processing and storage of pathology samples. The 
usage of FFPE tissues for chromatin immunoprecipitation combined with massively 
parallel DNA sequencing (ChIP-seq) has been hampered by the difficulty of preparing 
good quality chromatin. Recent advances in extracting chromatin from FFPE tissues will 
enable us to perform ChIP-seq in large series of AITL samples stored in pathology 
departments (Dolken et al., 1996; Jang et al., 2015; Koues et al., 2015). 
Additionally, acetylation of H3K27ac is mutually exclusive with H3K27me3. It will 
be of value to study the localization of H3K27ac, which is associated with gene 
regulatory regions, including enhancers and super-enhancers (SE). SEs can regulate 
spatiotemporal gene expression encompassing important genes associated with cell 
identity and genetic risk of diseases. Previous epigenomic analysis (H3K27ac 
enrichment) of normal lymphoid tissues, DLBCL cell lines, and primary tumor samples 
revealed SEs as characteristic features of normal and neoplastic human lymphoid 
tissues (Chapuy et al., 2013). We will analyze the SEs of AITL with or without IDH2 
mutations and try to identify key regulatory factors altered by mutant IDH2. The 
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proposed future studies will improve our understanding of genetic and epigenetic 
alterations in PTCL. 
What is the role of 5hmC in the pathogenesis of AITL? 
DNA methylation patterns are abnormal in human cancers, which usually show 
global hypomethylation and acquisition of DNA hypermethylation at the CpG islands. 
The demethylation process can occur either in a passive or an active manner. For 
passive demethylation, complete removal of DNA methylation in a population of cells 
requires many cycles of cell division in absence of DNMT1 activity at the affected site. In 
the active demethylation process, TET proteins are responsible for oxidation of 5mC to 
5hmC, which can be detected and quantified in mammalian tissues. However, 5fC and 
5caC, the further sequential oxidation products, are at very low levels and difficult to 
detect. 5hmC was first thought to be only an intermediate in the process of DNA 
demethylation, but was later proven to be a rather stable epigenetic mark. It may be 
recognized by specific proteins or competitively bind with 5mC related proteins, such as 
methyl-CpG binding protein 2 (Jin et al., 2010; Mellen et al., 2012; Yildirim et al., 2011). 
Several techniques, including Tet associated bisulfate sequencing (TAB)-RRBS 
(Hahn et al., 2015), have been developed to study the genome-wide distribution of 
5hmC at single-base resolution. 5hmC is mapped to promoters, enhancers, and gene 
bodies, but the level varies depending on the cell type. Moreover, 5hmC in a gene body 
is positively correlated with expression of the gene. 5hmC is significantly depleted in 
human cancers. As discussed in Chapter 4, 5hmC is decreased in T cells or AITL with 
IDH2 mutations. Therefore, it is worth assessing the global changes of 5hmC in AITL 
cases with or without IDH2 and TET2 mutations and associating the changes with gene 
expression using GEP data. 
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Can 2HG be transferred from IDH2R172 mutation-bearing malignant cells to 
surrounding stromal cells? 
When we compared the gene expression profiles of IDH2 mutated and wild-type 
AITL cases, the mutated cases tend to form a single large cluster, and there are many 
stroma-associated genes that are differentially expressed. A recent study reported that 
mice with xenografts of U87 tumor harboring an IDH2R140 mutation developed 
cardiomyopathy similar to that observed in mice carrying the IDH2 mutant transgene, 
suggesting a paracrine effect of 2HG from the tumor (Akbay et al., 2014). 2HG is indeed 
found at high levels in plasma of patients with IDH2 mutant tumors and in culture 
supernatants of Jurkat cells transduced with mutant IDH2. These observations support 
the hypothesis that the oncometabolite 2HG may be transmitted to the tumor 
microenvironment (ME) and induce changes that are the substrate for selection during 
tumor/ME co-evolution to promote the development and progression of AITL. If this 
hypothesis is substantiated, it provides a strong rationale for identifying critical target 
genes with aberrant methylation in both the ME and tumor that can contribute to 
neoplastic transformation. It would also suggest that therapies that reverse abnormal 
hypermethylation may be a novel approach in treating AITL with TET2 and/or IDH2 
mutations and may be more effective for the latter, as it may also disrupt tumor/stromal 
interactions. 
We tested this hypothesis in a preliminary study using a hanging drop 3D co-
culture platform (Perfecta3D Hanging Drop Plates) of Jurkat cells expressing wild-type or 
mutant IDH2 with stromal cells (293T, HS-5, or NIH 3T3 cells). 3D multicellular tumor 
spheroids more closely resemble the in vivo situation with regard to cell shape and 
cellular environment and can better mimic the growth condition of primary tumors in vivo 
than conventional 2D cultures. This is important for our study since AITL is a 
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microenvironment-dependent tumor. This model was utilized to study the effects of 
ectopically expressed mutant IDH2 in Jurkat on the surrounding stromal cells. We 
hypothesized that 2-HG generated by mutant IDH2 in transduced Jurkat cells can affect 
surrounding stromal cell through direct cell-cell interaction or though intercellular 
fluid/microsomes. We collected the culture medium and harvested the cells at day 9 and 
then separated the Jurkat cells by pipetting and digestion with 0.05% trypsin and FACS 
using CD45.  2HG was detected in the IDH2 mutation-bearing Jurkat cells and the 
culture medium, but was not detected in the co-cultured stromal cells. There are several 
possible explanations. The level of 2HG in the stromal cells might be too low to be 
detected. A high concentration is needed to inhibit dioxygenases, so a low, undetectable 
level probably has no functional significance. The 2HG generated by the mutation-
bearing Jurkat cells may not be efficiently transmitted to the surrounding stroma because 
of the inability of 2HG to enter cells and few microsomes are shed. Alternatively, the 3D 
co-culture of Jurkat and stromal cells may not mimic the condition in vivo. Stromal cells 
may differ in their ability to take up HG such as pinocytosis. Further investigations are 
needed to examine all these possibilities. Using isolated malignant cells and stromal 
cells in fresh AITL samples or from xenograft mice model would be beneficial to clarify 
the possibilities. 
Study of cooperative effects of mutations affecting epigenetic regulators in animal 
models 
Mutations affecting IDH2, TET2, and DNMT3A have been reported in myeloid 
and lymphoid malignancies. Investigations of these mutations and their cooperative 
effects are hampered by the lack of appropriate cell-based models for AITL and PTCL-
NOS. Contribution of these mutations to initiationand progression to hematopoietic 
malignancies may be studied in animal models. 
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Functional studies of TET2 mutations have been performed using several distinct 
knockout or knockdown mouse models. Conditional knock out of Tet2 in hematopoietic 
compartment showed increased self-renewal capacity of hematopoietic stem cells, 
enhanced competitive repopulation capacity, and eventual development of a CMML-like 
disease, suggesting that TET2 contributes to myeloid transformation (Moran-Crusio et 
al., 2011). A study using Tet2 gene trap mice showed that middle-aged Tet2 knockdown 
mice exhibited increased numbers of Tfh-like cells in the spleen and eventually 
developed T-cell lymphomas with Tfh-like features after a long latency (Muto et al., 
2014). This mouse model suggests that TET2 mutations found in AITL and PTCL-NOS 
contribute to their pathogenesis, likely through abnormal epigenetic alterations. 
The animal models mentioned above indicate additional mutations are needed to 
drive full transformation. TET2 mutations co-occur with other mutations affecting 
epigenetic regulators in PTCL. Recently, the cooperative effects of TET2 inactivation 
and DNMT3AR882H mutations were studied using a murine bone marrow transplantation 
assay (Scourzic et al., 2016). Primary recipient mice engrafted with Tet2-/-DNMT3AR882H 
progenitors developed T-ALL like, AML-like, or AITL-like diseases, and 75% of mice 
serially engrafted with Tet2-/-DNMT3AR882H progenitors developed an AITL-like disease 
closely resembling the human lymphoma. Tak Mak`s group developed a conditional 
IDH1R132 knock-in mice model to study the role of IDH mutations in the pathogenesis of 
AML. Conditional knock-in in the myeloid linease (LysM) showed age-dependent 
splenomegaly, an increase in lineage-restricted progenitors, and extramedullary 
hematopoiesis. Several studies showed IDH mutations alone do not transform 
hematopoietic cells. Mutant IDH1 cooperates with other genes, such as HoxA9 which is 
overexpressed in IDH1 mutant AML patients, to generate a MPD-like myeloid leukemia 
(Chaturvedi et al., 2013). Mutant IDH2 cooperates with mutant NPM1 to activate HoxA9 
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and hypoxia pathways in AML (Ogawara et al., 2015). Mice expressing a tissue-specific 
and tetracycline-inducible IDH2R140Q transgene showed aberrant hematopoiesis. 
IDH2R140Q and Flt3ITD cooperated in leukemia initiation and progression (Kats et al., 
2014). Potentially collaborating partners of mutant IDH2 in T cell lymphoma need to be 
investigated. 
Unlike the case in AML, IDH2 mutation and TET2 mutations co-occur frequently 
in AITL. To study the cooperative effects of IDH2 and TET2 mutations in T cells, we can 
utilize an adoptive transfer model. OTII mice express the mouse TCRα and TCRβ chains 
that pairs with CD4 coreceptor and is specific for chicken ovalbumin 323-339. TET2-/- 
OTII T-cells will be transduced with a retrovirus expressing IDH2R172K together with a 
marker. We will monitor tumor generation and the differentiation of different subsets of 
CD4+ T cells after repeated stimulation of recipient mice with OVA. TET2-/- OTII T-cells 
and TET2+/+ OTII will be used as control. TET2+/- mice should be included since the 
hypomorphic gene trap mice seem to generate tumors more efficiently than TET2-null 
mice.  
Is IDH2 mutation a potential therapeutic target for AITL? 
Despite a better understanding of the pathogenesis of T cell lymphoma, effective 
therapy for this group of disease, particularly AITL, is needed. As discussed in Chapter 4, 
current findings give a strong rationale for the use of hypomethylating agents and HDAC 
inhibitors in AITL treatment. TET2-mutated MDS patients have been shown to respond 
to hypomethylating agents (Hnisz et al., 2013). A case report using 5-azacytidine to treat 
a patient with chronic CMML, who also had TET2-mutant AITL, led to a complete 
remission of both the AITL and CMML (Loven et al., 2013). Thus, investigation of the 
clinical efficacy of demethylating agent 5-azacytidine combined with an HDAC inhibitor, 
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such as Romidepsin, is worth pursuing in the treatment of AITL cases with IDH2 and/or 
TET2 mutations. 
IDH2 mutation has been proposed to be a novel target for AML treatment. Small 
molecules have been developed to block the generation of 2HG from mutant IDH 
proteins. AG-221 is a potent and orally available compound that is highly selective for 
the IDH2R140 mutant enzyme (Stein, 2015). TF-1 erythroleukemia cells carrying 
IDH2R140Q mutation showed growth factor–independent proliferation and a block in 
erythroid differentiation that was reversed by IDH2 inhibitor treatment (Wang et al., 
2013).  A recent phase I study with AG-221 (using continuous oral dosing once or twice 
daily, 28-day cycles) in AML patients has produced highly promising results with very 
low toxicity.  
AG-120, a selective inhibitor of IDH1 mutant, showed similar effects in early 
stage of clinical trials. It is worth mentioning that AG-221 is more specific in inhibiting 
IDH2R140 mutations, which account for 80% of IDH2 mutation in AML.  With AG-221 
treatment, 2HG is decreased up to 98% in patients with IDH2R140Q mutation, but 
treatment is less effective (up to 88%) for patients with IDH2R172K mutation.  To date, all 
IDH2 mutations identified in T cell lymphomas affect R172. The basis for this preference 
needs further investigation, and a more specific inhibitor needs to be developed for the 
treatment of AITL. 
 
 
134	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Patient samples and cell lines 
In Chapter 4, we included 90 molecularly defined PTCL cases with GEP and clinical 
outcome data as well as two pathologically diagnosed cases (Iqbal et al., 2009). This 
study was approved by the Institutional Review Board of the University of Nebraska 
Medical Center and City of Hope Medical Center. Jurkat cells (Clone E6-1, ATCC® TIB-
152™) were cultured in 10 mM HEPES-buffered RPMI 1640 (Invitrogen) supplemented 
with 10% fetal bovine serum, penicillin G (100 U/ml) and streptomycin (100 µg/ml) at 37 
ºC in a 5% CO2 atmosphere.  
Quantification of TCR transcripts 
TCR gene sequences were downloaded from the international ImMunoGeneTics 
information system (IMGT) (doi: 10.1093/nar/27.1.209; doi: 10.1093/nar/gku1056). 
Kallisto (v0.42; http://arxiv.org/abs/1505.02710) was used to quantify the transcript 
abundance of each TCR gene, which was normalized to transcripts per million reads 
(TPM).  
Identification of CDR3 sequences 
MiXCR (v1.2; doi:10.1038/nmeth.3364) was used to extract apparent CDR3 sequences 
from RNA-seq data. After MiXCR analysis, additional filtering steps were used to 
exclude sequences transcribed from non-TCR loci. First, reads that contained apparent 
CDR3 sequences were aligned against the human reference genome (hg19) using 
BLAT (version 34, default setting). Reads that had a >80% match with non-TCR 
sequences and that did not alternatively match with any TCR sequence as reported from 
the BLAT output were considered paralog reads and were removed. Second, the CDR3 
nucleotide sequence of each clone was also aligned against the human reference 
genome (hg19) using BLAT, and clone sequences with nearly complete matches (>90% 
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match) were removed. Third, in order to avoid noise from unknown sequences, clones 
with CDR3 sequences that were recurrently found in more than three patient cases were 
removed. The corresponding V and J segments in CDR3 sequences were indicated by 
MiXCR. In particular, somatically mutated immunoglobulin κ CDR3 regions may 
resemble those of TCRα. The frequencies of the top 10 most frequent CDR3 were 
determined in each case as illustrated. A case was considered having a clonal 
population if the sum of the top two CDR3α or CDR3β clones was >10X the third highest.  
Mutation analysis of RNA-seq data 
Raw RNA sequencing reads were mapped against the human reference genome (hg19) 
using Tophat (v2.0.10) (Kim et al., 2013) with default settings. Samtools and Varscan 
(v2.3.6) (Koboldt et al., 2012) were used to call the variants. To remove artifacts, we 
required minimal read depth of 10, including at least 4 reads supporting the variants, and 
allele frequency no less than 5%. SNPs in dbSNP (v138) were excluded.  
Identification of EBV infection in PTCL using RNA-seq 
Sequences were mapped against EBV genome (AJ507799.2) using Burrows-Wheeler 
Aligner (v0.7.5) and analyzed with Samtools (v.0.6.1) (Li et al., 2009). Samples with 100 
or more EBV-derived reads were classified as EBV-positive (Supplementary Figure 6). 
Isolation and growth of primary human CD4+ T cells 
Normal human CD4+ T cells were isolated from peripheral blood lymphocytes of healthy 
donors (Miltenyi Biotec) and were cultured in medium as mentioned above with IL-2 (30 
U/ml) (R&D systems) and anti-CD3/CD28 Dynabeads (Invitrogen). 
Transfection and transduction  
Of the several IDH2 mutants in AITL, IDH2R172K is the most common variant in AITL with 
in vitro (Yan et al., 2009) enzymatic activity similar to that of other variants (e.g. 
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IDH2R172M and IDH2R172G), and was utilized for the functional studies. A IDH2R172K mutant 
was generated by standard site-directed mutagenesis introducing a G515A base change 
in the IDH2 open reading frame (ORF) on a wild-type IDH2 cDNA clone from Open 
Biosystems (Huntsville, AL). The sequence was verified by Sanger sequencing 
(Invitrogen, Grand Island, NY). We further added a FLAG-epitope sequence to the C-
terminus of wild-type and mutant IDH2 and subcloned these sequences upstream of the 
internal ribosomal entry site (IRES) sequence of a retroviral vector, murine stem cell 
virus (pMIG). Retrovirus was generated using HEK 293T cells, and vectors carrying 
IDH2R172K or wild-type IDH2 were transduced into the Jurkat T-cells or primary CD4+ T 
cells as previously described (Ward et al., 2013). GFP+ cells were sorted by 
FACSCalibur flow cytometer on day 3 after transduction (BD Bioscience, San Jose, CA). 
Gene expression profiling (GEP) and pathway analysis 
GEP was performed and reported in a previous study (Iqbal et al., 2009) using HG-
U133-plus 2.0 arrays (Affymetrix). BRB Array Tools (http://linus.nci.nih.gov/BRB-
ArrayTools.html) was used for unsupervised hierarchical clustering and for determining 
significant differences in gene expression among pre-defined groups: IDH2/TET2 
double-mutant, TET2 single-mutant, and wild-type AITL using normalized log2-
transformed signals. We used Ingenuity pathway analysis (IPA, Qiagen) list to perform 
functional annotation. The GSEA algorithm (http://www.broad.mit.edu/gsea/) 
(Subramanian et al., 2005) was used to identify a leading edge set of the genes that best 
distinguished IDH2/TET2 double-mutant and TET2 single-mutant AITL. 
Targeted re-sequencing of TET2, DNMT3A and RHOA genes 
We used TruSeq Custom Amplicon (TSCA) design (Illumina) to interrogate the entire 
coding regions of TET2, DNMT3A, and RHOA in genomic DNA. Twenty-five cycles of 
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amplification were used for 250 ng genomic DNA per sample. We used the Mutascope 
algorithm for sequence analysis (Ward et al., 2010). 	  
Sanger sequencing and pyrosequencing of IDH2 
Mutational analysis of the IDH2 gene was performed by bi-directional Sanger 
sequencing (Cairns et al., 2012)	    and pyrosequencing using primers that specifically 
amplify R140 or R172 regions. To perform PCR reactions, 32 ng of DNA was used as 
template. The PCR reactions were performed in a total volume of 25 µl for 35 cycles 
using Roche Diagnostic Corporation (Indianapolis, IN) FastStart Taq DNA Polymerase 
(1.0U), MgCl2 solution (3.5 mM), dNTP’s (0.2 mM), sense primer (0.24 uM), antisense 
primer (0.18 µM), with denaturation at 95 ºC for 30 seconds, annealing temperature for 
45 seconds at the annealing temperature indicated in Table 1, and extension at 72 ºC for 
1 minute. Before proceeding with all analyses, all PCR products were electrophoresed 
on a 0.8% agarose gel, stained with ethidium bromide, and visualized for appropriate 
and pure product using a Bio-Rad Laboratories (Hercules, CA) Gel-Doc UV illuminator. 
Sequence mutation was determined using a Qiagen (Valencia, CA) Pyromark Q24 
pyrosequencer and the sequencing primer indicated in Table 4.2, according to the 
manufacturer’s recommendations. 
Liquid chromatography coupled to tandem mass spectrometry analysis of 2HG, 
5mC, and 5hmC in genomic DNA 
2-HG was quantified using reverse-phase liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS) as previously described (Gross et al., 2010). DNA 
hydrolysis was performed as described previously (Le et al., 2011) with slight 
modifications. Genomic DNA was extracted from Jurkat cells or primary CD4+ T cells 
transduced with vectors carrying wild-type IDH2 or IDH2R172, using DNeasy Blood and 
Tissue Kit (Qiagen Inc, MD). DNA hydrolysis was performed as described previously (Le 
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et al., 2011) with slight modifications. Briefly, in a 25 µl reaction volume, 1 µg of genomic 
DNA was mixed with 1 µl of DNA Degradase Plus (E2020, Zymo Research, Inc CA) and 
2.5 µL of 10X reaction buffer. After incubation at 37 °C for an hour, the reaction was 
inactivated by adding 175 µl of 0.1% formic acid to yield a final concentration of 5 ng of 
digested DNA/µl. Standards of 5-methylcytosine and 5-hydroxymethylcytosine DNA 
(D5405, Zymo Research Inc, CA) were used to generate a calibration curve. The 
nucleosides from DNA hydrolysis were analyzed on a Waters ACQUITY ultra 
performance liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to an 
Applied Biosystem 4000 Q TRAP® quadrupole linear ion trap hybrid mass spectrometer 
with an electrospray ionization (ESI) source (Applied Biosystems, MDS Sciex, Foster 
City, CA). Samples were injected into a ZORBAX RRHD C18 column (Eclipse Plus, 2.1 x 
50 mm, 1.7 µm; Agilent) and eluted with isocratic profile (95% water containing 0.1% 
formic acid and 5% methanol). Multiple reaction monitoring (MRM) mode (5mC m/z 
242.1à126.1, 5hmC 258.1à142.1 and dC m/z 228.1à112.1) was used for 
quantification. The percentages of 5hmC and 5mC were calculated by using the 
individual MRM peak area divided by the combined peak areas (5mC + 5hmC + C). All 
the measured values were corrected using the calibration curve of the standard samples. 
Methylation Sensitive Cut Counting (MSCC) for global methylation analysis 
The genomic DNA was treated with a methyl-sensitive restriction endonuclease HpaII 
which can cut all unmethylated 5`-CCGG-3` sites. An adaptor sequence containing an 
MmeI-recognition site is ligated to the digested genomic DNA. After digestion with MmeI 
restriction enzyme, which cuts 18 and 20 nt from its recognition site, a second adaptor is 
ligated to the broken end. Finally all constructs were sequenced on an Illumina GAIIx. 
The number of sequencing reads correlates with the DNA methylation status of each 
HpaII recognition site in the CpG islands. Unmethylated sites generate a high number of 
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reads. In other words, lower counts are associated with higher methylation at 5’-CCGG-3’ 
sites. The sequenced tags were aligned to the genomic locations using the sequence 
aligner Bowtie.  To analyze the data, we used the methylation counts in CpG islands of a 
set of highly expressed housekeeping genes in AITL to normalize the counts from each 
case. 
Reduced Representation Bisulfite Sequencing (RRBS) for methylation analysis 
RRBS was performed as described (Kucuk et al., 2015) with some modifications. Briefly, 
1.5 µg of genomic DNA was digested with the methylation-insensitive restriction enzyme 
MspI (NEB, Ipswich, MA) at 37°C for overnight and purified with QIAquick Nucleotide 
Removal Kit (Qiagen Inc, MD). Ends of each restriction fragment were filled in and a 3’ 
adenosine was added with Klenow Fragment [3’→5’ exo-minus; (NEB, Ipswich, MA)]. 
Methylated paired-end Illumina adapters were ligated to the ends of the DNA fragments 
using T4 DNA Ligase (Promega, Madison, WI). Insert fragments between 40 bp and 380 
bp were purified by Ampure XP double bead size selection (Agencort). Bisulfite 
conversion was done with EZ DNA Methylation kit (Zymo, Irvine, CA), and the library 
was amplified with Pfu Turbo Cx Hotstart DNA Polymerase (Agilent, Santa Clara, CA). 
The final PCR products were run on 6% TBE polyacrylamide gels and fragments of 160-
500 bp were excised and eluted with EB buffer. The libraries were sequenced (Illumina 
HiSeq2500) and yielded about 40 million 100-nucleotide paired-end reads per sample. 
Trim Galore (v0.3.7) (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore) 
was used to trim low-quality sequences and remove Illumina adaptor sequences from 
the raw paired-end reads with default parameters and the “rrbs” option on. Bismark 
Bisulfite Mapper (v0.12.5) (Guo et al., 2016) was used to map the high-quality trimmed 
RRBS reads against the human reference sequence (hg19) and to extract BedGraph 
files. The regions of promoter, gene body, and intergenic region have been previously 
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defined (Marcu et al., 1992). CpG island shores were defined as regions bordering CpG 
islands within 2 kb. Each CpG site was assigned to a single gene for the global 
methylation analysis, but could be assigned to multiple genes for individual gene 
analysis based on the CpG location. For individual CG sites, we calculated the 
methylation ratio by using the total number of methylated reads divided by the total 
number of reads at the site. We then derived an average methylation ratio for all CG 
sites in the promoter region (TSS ± 1kb) for each gene; this value was used for most 
subsequent statistical analyses. Poised genes were defined as those in which the 
proportion of the promoter in hESCs with a “poised” chromatin pattern is greater than 
that with either an “active” or “weak” promoter chromatin pattern (genome.ucsc.edu, file 
wgEncodeBroadHmmH1hescHMM.bed). 
Histone trimethylation analysis by Immunohistochemistry 
We performed immunohistochemical staining on tissue microarray sections of AITL with 
1:100 rabbit polyclonal anti-H3K27me3 (07-449, Millipore) and 1:400 rabbit polyclonal 
anti-H3K9me3 (ab8898, Abcam) as previously described (Iqbal et al., 2014). The stained 
sections were scanned by Ventana’s iScan Coreo slide scanner (Ventana Medical 
Systems) using a 40 x 0.25 objective and exported into ImageScope analysis software 
(Leica Microsystems) for quantification. The signal threshold for nuclei in the negative 
control was determined and applied to all scanned images.  Areas above the signal 
threshold were automatically measured and divided into weak-positive, positive and 
strong-positive based on the signal intensities.  
Protein/ histone extraction and western blotting  
Whole cell lysates were prepared as previously described (Kucuk et al., 2015), and 
histones were isolated using a histone extraction kit (ab113476, Abcam). Protein was 
separated by 10% SDS-PAGE and transferring to PVDF membrane (Bio-Rad) (Kucuk et 
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al., 2015). After incubation with primary antibody (listed in Table 4.2) overnight at 4°C, 
the membrane was washed and incubated with anti-mouse IgG HPR-linked secondary 
antibody (7076S, Cell Signaling) at 1:10,000 or anti-rabbit IgG HPR-linked secondary 
antibody (7074S, Cell Signaling) at 1:10,000 according to the primary antibody used. A 
Western ECL substrate (170-5060, Bio-Rad) was used for detection of HRP. 
Statistical analyses  
Continuous variables were compared with Wilcoxon rank sum test or two-tailed 
Student’s t-test. Categorical variables between patients with and without IDH2R172 
mutations were compared using chi-square test or Fisher’s exact test. For unsupervised 
hierarchical analysis, we used Fisher's exact test to determine the significance of the 
tendency of neighboring cases on the dendrogram to have identical mutation status. All 
tests were two-sided, unless otherwise specified, and significance was set at P < 0.05. 
The overall survival distribution (OS; death from any cause) was estimated using the 
Kaplan-Meier method and differences were assessed using the log rank test. Statistical 
analyses were performed with R-language statistical packages or GraphPad Prism 6. 
Significant differences among groups were considered at P values below 0.05 (*).  P 
values below 0.01, 0.001 and 0.0001 were denoted as **, *** and ****. 
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